K200 제약·바이오 12종목 — 국채 옆의 배당, 매출·이익 성장, R&D 자산화, 지분 구조K200 pharma and biotech, 12 companies — dividends next to government bonds, revenue and profit growth, R&D capitalisation, ownership structureK200製薬・バイオ12銘柄 — 国債と並べた配当、売上高・利益の成長、R&D資産化、持株構造
셀트리온·삼성바이오로직스·대웅(지주)을 중심으로 K200 제약·바이오 12종목의 DART 정기보고서(2019Q1~, 원문 표·주석 포함)를 같은 틀로 편다. 배당·이익수익률을 KTB/UST 10Y 옆에 놓고, 매출·영업이익·순이익 성장, 연구개발비와 개발비 자산화, CapEx·생산능력·가동률, 재고·매출채권, 특수관계자 매출(셀트리온↔헬스케어·삼바↔에피스), 최대주주·자기주식, 합병·분할 문장을 Raw Data 그대로 적는다.The DART periodic reports (2019Q1 onwards, original tables and notes included) of the 12 K200 pharma and biotech companies are laid out in one frame, centred on Celltrion, Samsung Biologics and Daewoong (hold.). Dividend and earnings yields sit next to KTB/UST 10Y; revenue, operating-profit and net-profit growth, R&D spending and capitalised development costs, capex, capacity and utilisation, inventories and receivables, related-party sales (Celltrion↔Celltrion Healthcare · Samsung Biologics↔Samsung Bioepis), largest shareholders and treasury shares, and merger and spin-off text are set down as in the Raw Data.Celltrion・Samsung Biologics・Daewoong (hold.)を中心に、K200製薬・バイオ12銘柄のDART定期報告書(2019Q1以降、原文の表・注記を含む)を同じ枠組みで並べる。配当利回り・益回りをKTB/UST 10Yと並べ、売上高・営業利益・純利益の成長、研究開発費と開発費の資産化、設備投資・生産能力・稼働率、棚卸資産・売上債権、関連当事者向け売上(Celltrion↔Celltrion Healthcare・Samsung Biologics↔Samsung Bioepis)、筆頭株主・自己株式、合併・分割の文章をRaw Dataのまま記す。
기준일 20261027As of 20261027基準日 20261027DART 정기보고서(원문·재무제표·주요정보)DART periodic reports (original text · financial statements · key information)DART定期報告書(原文・財務諸表・主要情報)12종목 · 심층 셀트리온 · 삼성바이오 · 대웅(지주)12 companies · deep dives: Celltrion · Samsung Bio · Daewoong (hold.)12銘柄 · 深掘り Celltrion · Samsung Bio · Daewoong (hold.)
먼저 보는 세 줄 · 2026-10-27Three lines first · 2026-10-27まず見る三行 · 2026-10-27
셀트리온 2026Q3 잠정 매출 15,755억 (YoY +53.1%) · 영업이익 5,253억 — 관세청 완제 수출 연결은 전진 검증 6분기 중 3분기만 직전 분기 유지를 이겨 우리 Fcst 를 내지 않았다.Celltrion 2026Q3 preliminary revenue 15,755 KRW 100mn (YoY +53.1%) · operating profit 5,253 KRW 100mn — the link to customs dose-form exports beat holding the previous quarter in only 3 of 6 forward-test quarters, so we did not publish our Fcst.Celltrion 2026Q3速報売上高15,755億ウォン(YoY +53.1%) · 営業利益5,253億ウォン — 関税庁の完成品輸出との連動はフォワードテスト6四半期中3四半期しか前四半期据え置きに勝てず、当サイトFcstは出さなかった。
삼성바이오 매출 FY2025Samsung Bio revenue FY2025Samsung Bio 売上高 FY2025
4.56조KRW trn兆ウォン
YoY +0.2% · OPM +45.4%
숫자는 DART 정기보고서(원문 표·재무제표)와 영업(잠정)실적 공정공시에서 옮겼다. 분기 4분기 = 연간 − 9개월 누계. 삼성바이오로직스 분기는 에피스 분할 전후 범위를 맞추려 별도(CDMO) 기준. 관세청 수출은 한국 전체 합. 우리 Fcst 는 자체 추정(컨센서스 아님).Figures are taken from DART periodic reports (original tables and financial statements) and fair-disclosure filings of preliminary operating results. Quarterly Q4 = full year − nine-month cumulative. Samsung Biologics' quarters are on a separate (CDMO) basis to keep the scope the same before and after the Samsung Bioepis spin-off. Customs exports are Korea-wide totals. Our Fcst is our own estimate (not consensus).数値はDART定期報告書(原文の表・財務諸表)と営業(暫定)実績の公正開示から転記した。四半期の第4四半期 = 通期 − 9か月累計。Samsung Biologicsの四半期はSamsung Bioepis分割前後の範囲をそろえるため個別(CDMO)ベース。関税庁の輸出は韓国全体の合計。当サイトFcstは独自推計(コンセンサスではない)。
한 표 — 12종목을 같은 잣대로One table — 12 companies on the same yardstick一覧表 — 12銘柄を同じ物差しで
한 표One table一覧表K200 pharma & biotech: growth, profitability, R&D, capital return, ownership (latest fiscal year)
회사
FY
매출
YoY
CAGR
영업이익률
순이익
ROE
R&D/매출
R&D 자산화
CapEx/매출
배당수익률
배당−KTB(연말)
이익수익률
최대주주
자기주식
삼성바이오
FY2025
4.56조
+0.2%
+36.6% (2019~)
+45.4%
1.78조
+19.4%
3.7%
—
+32.4%
무배당
—
—
삼성물산 43.1%
0.1%
셀트리온
FY2025
4.16조
+17.0%
+24.3% (2019~)
+28.1%
1.03조
+5.9%
11.6%
56.3%
+8.0%
0.4% (FY2025)
-2.98%p
2.5%
(주)셀트리온홀딩스 25.9%
1.7%
유한양행
FY2025
2.19조
+5.7%
+6.7% (2019~)
+4.8%
0.19조
+8.8%
11.1%
3.3%
+6.1%
0.5% (FY2025)
-2.88%p
2.2%
유한재단 15.9%
7.6%
대웅(지주)
FY2025
2.07조
+6.8%
+7.2% (2019~)
+12.7%
0.23조
+16.1%
n/a
—
+16.8%
0.9% (FY2025)
-2.48%p
19.3%
윤재승 11.6%
27.7%
GC녹십자
FY2025
1.99조
+18.5%
+6.4% (2019~)
+3.5%
-0.03조
-0.4%
8.6%
3.6%
+5.3%
0.9% (FY2025)
-2.48%p
-0.2%
㈜녹십자홀딩스 50.1%
2.3%
종근당
FY2025
1.69조
+6.7%
+7.8% (2019~)
+4.8%
0.08조
+8.2%
11.0%
16.5%
+10.6%
0.6% (FY2025)
-2.78%p
7.1%
(주)종근당홀딩스 26.7%
4.5%
대웅제약
FY2025
1.57조
+10.4%
+5.9% (2019~)
+12.5%
0.19조
+21.8%
15.8%
11.0%
+15.4%
0.3% (FY2025)
-3.08%p
8.5%
(주)대웅 52.3%
0.7%
한미약품
FY2025
1.55조
+3.5%
+5.6% (2019~)
+16.7%
0.19조
+14.5%
14.8%
8.0%
+4.9%
0.8% (FY2025)
-2.58%p
5.3%
한미사이언스(주) 41.4%
1.0%
SD바이오센서
FY2025
0.71조
+2.3%
-15.9% (2020~)
-11.4%
-0.51조
-19.5%
n/a
—
+8.1%
2.2% (FY2025)
-1.18%p
-47.8%
조영식 27.2%
0.9%
SK바이오팜
FY2025
0.71조
+29.1%
+33.7% (2019~)
+28.9%
0.25조
+39.3%
24.7%
—
+4.2%
무배당
—
—
SK(주) 50.1%
n/a
SK바이오사이언스
FY2025
0.65조
+143.5%
-8.5% (2021~)
-19.0%
-0.06조
-3.2%
23.9%
37.3%
+40.0%
무배당
—
—
SK케미칼(주) 66.3%
0.5%
한올바이오파마
FY2025
0.16조
+11.7%
+6.2% (2019~)
-0.6%
-0.01조
-3.4%
20.9%
39.5%
+9.1%
무배당
—
—
(주)대웅제약 30.8%
2.6%
Company
FY
Revenue
YoY
CAGR
Operating margin
Net profit
ROE
R&D / revenue
R&D capitalised
Capex / revenue
Dividend yield
Dividend − KTB (year-end)
Earnings yield
Largest shareholder
Treasury shares
Samsung Bio
FY2025
KRW 4.56trn
+0.2%
+36.6% (from 2019)
+45.4%
KRW 1.78trn
+19.4%
3.7%
—
+32.4%
no dividend
—
—
Samsung C&T 43.1%
0.1%
Celltrion
FY2025
KRW 4.16trn
+17.0%
+24.3% (from 2019)
+28.1%
KRW 1.03trn
+5.9%
11.6%
56.3%
+8.0%
0.4% (FY2025)
-2.98pp
2.5%
Selteurionholdingseu 25.9%
1.7%
Yuhan
FY2025
KRW 2.19trn
+5.7%
+6.7% (from 2019)
+4.8%
KRW 0.19trn
+8.8%
11.1%
3.3%
+6.1%
0.5% (FY2025)
-2.88pp
2.2%
Yuhanjaedan 15.9%
7.6%
Daewoong (hold.)
FY2025
KRW 2.07trn
+6.8%
+7.2% (from 2019)
+12.7%
KRW 0.23trn
+16.1%
n/a
—
+16.8%
0.9% (FY2025)
-2.48pp
19.3%
Yun Jaeseung 11.6%
27.7%
GC Biopharma
FY2025
KRW 1.99trn
+18.5%
+6.4% (from 2019)
+3.5%
KRW -0.03trn
-0.4%
8.6%
3.6%
+5.3%
0.9% (FY2025)
-2.48pp
-0.2%
GC 50.1%
2.3%
Chong Kun Dang
FY2025
KRW 1.69trn
+6.7%
+7.8% (from 2019)
+4.8%
KRW 0.08trn
+8.2%
11.0%
16.5%
+10.6%
0.6% (FY2025)
-2.78pp
7.1%
Chongkundang Holdings 26.7%
4.5%
Daewoong Pharm
FY2025
KRW 1.57trn
+10.4%
+5.9% (from 2019)
+12.5%
KRW 0.19trn
+21.8%
15.8%
11.0%
+15.4%
0.3% (FY2025)
-3.08pp
8.5%
Daewoong 52.3%
0.7%
Hanmi
FY2025
KRW 1.55trn
+3.5%
+5.6% (from 2019)
+16.7%
KRW 0.19trn
+14.5%
14.8%
8.0%
+4.9%
0.8% (FY2025)
-2.58pp
5.3%
Hanmi Science 41.4%
1.0%
SD Biosensor
FY2025
KRW 0.71trn
+2.3%
-15.9% (from 2020)
-11.4%
KRW -0.51trn
-19.5%
n/a
—
+8.1%
2.2% (FY2025)
-1.18pp
-47.8%
Jo Yeongsik 27.2%
0.9%
SK Biopharm
FY2025
KRW 0.71trn
+29.1%
+33.7% (from 2019)
+28.9%
KRW 0.25trn
+39.3%
24.7%
—
+4.2%
no dividend
—
—
SK 50.1%
n/a
SK Bioscience
FY2025
KRW 0.65trn
+143.5%
-8.5% (from 2021)
-19.0%
KRW -0.06trn
-3.2%
23.9%
37.3%
+40.0%
no dividend
—
—
SK Chemicals 66.3%
0.5%
HanAll
FY2025
KRW 0.16trn
+11.7%
+6.2% (from 2019)
-0.6%
KRW -0.01trn
-3.4%
20.9%
39.5%
+9.1%
no dividend
—
—
Daewoong Pharma 30.8%
2.6%
会社
FY
売上高
YoY
CAGR
営業利益率
純利益
ROE
R&D/売上高
R&D資産化
設備投資/売上高
配当利回り
配当−KTB(年末)
益回り
筆頭株主
自己株式
Samsung Bio
FY2025
4.56兆ウォン
+0.2%
+36.6%(2019〜)
+45.4%
1.78兆ウォン
+19.4%
3.7%
—
+32.4%
無配
—
—
Samsung C&T 43.1%
0.1%
Celltrion
FY2025
4.16兆ウォン
+17.0%
+24.3%(2019〜)
+28.1%
1.03兆ウォン
+5.9%
11.6%
56.3%
+8.0%
0.4%(FY2025)
-2.98%pt
2.5%
Selteurionholdingseu 25.9%
1.7%
Yuhan
FY2025
2.19兆ウォン
+5.7%
+6.7%(2019〜)
+4.8%
0.19兆ウォン
+8.8%
11.1%
3.3%
+6.1%
0.5%(FY2025)
-2.88%pt
2.2%
Yuhanjaedan 15.9%
7.6%
Daewoong (hold.)
FY2025
2.07兆ウォン
+6.8%
+7.2%(2019〜)
+12.7%
0.23兆ウォン
+16.1%
n/a
—
+16.8%
0.9%(FY2025)
-2.48%pt
19.3%
Yun Jaeseung 11.6%
27.7%
GC Biopharma
FY2025
1.99兆ウォン
+18.5%
+6.4%(2019〜)
+3.5%
-0.03兆ウォン
-0.4%
8.6%
3.6%
+5.3%
0.9%(FY2025)
-2.48%pt
-0.2%
GC 50.1%
2.3%
Chong Kun Dang
FY2025
1.69兆ウォン
+6.7%
+7.8%(2019〜)
+4.8%
0.08兆ウォン
+8.2%
11.0%
16.5%
+10.6%
0.6%(FY2025)
-2.78%pt
7.1%
Chongkundang Holdings 26.7%
4.5%
Daewoong Pharm
FY2025
1.57兆ウォン
+10.4%
+5.9%(2019〜)
+12.5%
0.19兆ウォン
+21.8%
15.8%
11.0%
+15.4%
0.3%(FY2025)
-3.08%pt
8.5%
Daewoong 52.3%
0.7%
Hanmi
FY2025
1.55兆ウォン
+3.5%
+5.6%(2019〜)
+16.7%
0.19兆ウォン
+14.5%
14.8%
8.0%
+4.9%
0.8%(FY2025)
-2.58%pt
5.3%
Hanmi Science 41.4%
1.0%
SD Biosensor
FY2025
0.71兆ウォン
+2.3%
-15.9%(2020〜)
-11.4%
-0.51兆ウォン
-19.5%
n/a
—
+8.1%
2.2%(FY2025)
-1.18%pt
-47.8%
Jo Yeongsik 27.2%
0.9%
SK Biopharm
FY2025
0.71兆ウォン
+29.1%
+33.7%(2019〜)
+28.9%
0.25兆ウォン
+39.3%
24.7%
—
+4.2%
無配
—
—
SK 50.1%
n/a
SK Bioscience
FY2025
0.65兆ウォン
+143.5%
-8.5%(2021〜)
-19.0%
-0.06兆ウォン
-3.2%
23.9%
37.3%
+40.0%
無配
—
—
SK Chemicals 66.3%
0.5%
HanAll
FY2025
0.16兆ウォン
+11.7%
+6.2%(2019〜)
-0.6%
-0.01兆ウォン
-3.4%
20.9%
39.5%
+9.1%
無配
—
—
Daewoong Pharma 30.8%
2.6%
매출·이익은 DART 연결 재무제표, R&D 는 원문 '연구개발비용' 표(회사 기재 매출 대비 비율·개발비 자산화), 배당수익률은 DART 배당표의 회사 기재값(배당기준일 전 1주일 평균 종가), 이익수익률은 그 수익률로 역산한 주가에 연결 EPS. 오늘 KTB10Y 3.94% · UST10Y 4.98%.
Revenue and profit are from DART consolidated financial statements; R&D from the 'R&D expenses' table in the filings (the ratio to revenue the company reports, and capitalised development costs); dividend yield is the company-reported figure in the DART dividend table (average closing price over the week before the record date); earnings yield is consolidated EPS over the price implied by that yield. Today KTB10Y 3.94% · UST10Y 4.98%.
⚠ 규율: 무배당 회사(삼성바이오로직스 등)는 주가를 역산할 수 없어 이익수익률이 비어 있다. R&D 자산화 = 개발비(무형자산) ÷ 연구개발비용 계.
⚠ Discipline: For companies that pay no dividend (Samsung Biologics and others) the price cannot be backed out, so the earnings yield is blank. R&D capitalised = development costs (intangible assets) ÷ total R&D expenses.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
02
배당·이익수익률 — 국채 10Y 옆에Dividend and earnings yields — next to the 10-year government bond配当利回り・益回り — 10年国債と並べて
수익률Yield利回りDividend yield vs. KTB 10Y (fiscal year-end) — latest dividend year of each company
⚠ 규율: 제약·바이오는 배당으로 국채를 이기는 회사가 거의 없다 — 이 섹터의 '주식으로서의 의미'는 성장과 이익수익률 열에서 찾아야 한다.
⚠ Discipline: Almost no pharma or biotech company beats government bonds on dividends — the sector's 'meaning as an equity' has to be found in the growth and earnings-yield columns.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 배당수익률은 회사가 배당표에 적은 값(배당기준일 전 1주일 평균 종가 기준)이다. 국채는 그 회계연도 말 값. 무배당 회사는 빈칸.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Dividend yield is the figure the company reports in its dividend table (based on the average closing price over the week before the record date). Government bond yields are fiscal-year-end values. Companies that pay no dividend are left blank.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익수익률Earnings yield益回りEarnings yield (EPS ÷ implied price) vs. KTB 10Y
셀트리온 EY 2.5% vs KTB 3.38% → -0.9%p · 유한양행 EY 2.2% vs KTB 3.38% → -1.2%p · 대웅(지주) EY 19.3% vs KTB 3.38% → +15.9%p · GC녹십자 EY -0.2% vs KTB 3.38% → -3.6%p · 종근당 EY 7.1% vs KTB 3.38% → +3.7%p · 대웅제약 EY 8.5% vs KTB 3.38% → +5.1%p · 한미약품 EY 5.3% vs KTB 3.38% → +2.0%p · SD바이오센서 EY -47.8% vs KTB 3.38% → -51.2%p.
Celltrion EY 2.5% vs KTB 3.38% → -0.9pp · Yuhan EY 2.2% vs KTB 3.38% → -1.2pp · Daewoong (hold.) EY 19.3% vs KTB 3.38% → +15.9pp · GC Biopharma EY -0.2% vs KTB 3.38% → -3.6pp · Chong Kun Dang EY 7.1% vs KTB 3.38% → +3.7pp · Daewoong Pharm EY 8.5% vs KTB 3.38% → +5.1pp · Hanmi EY 5.3% vs KTB 3.38% → +2.0pp · SD Biosensor EY -47.8% vs KTB 3.38% → -51.2pp.
Celltrion 益回り2.5% vs KTB 3.38% → -0.9%pt · Yuhan 益回り2.2% vs KTB 3.38% → -1.2%pt · Daewoong (hold.) 益回り19.3% vs KTB 3.38% → +15.9%pt · GC Biopharma 益回り-0.2% vs KTB 3.38% → -3.6%pt · Chong Kun Dang 益回り7.1% vs KTB 3.38% → +3.7%pt · Daewoong Pharm 益回り8.5% vs KTB 3.38% → +5.1%pt · Hanmi 益回り5.3% vs KTB 3.38% → +2.0%pt · SD Biosensor 益回り-47.8% vs KTB 3.38% → -51.2%pt。
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 주가는 시세 Raw Data 가 아니라 회사가 적은 배당수익률로 역산했다(주당배당금 ÷ 배당수익률) — 배당하는 회사만.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: The price is not from the market-price Raw Data; it is backed out from the dividend yield the company reports (dividend per share ÷ dividend yield) — dividend payers only.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⚠ 규율: 합병·분할이 있는 회사는 지수가 사업 성장이 아니라 범위 변화를 담는다(셀트리온 2023 헬스케어 합병, 삼성바이오로직스 2025 에피스 분할).
⚠ Discipline: For companies with a merger or spin-off, the index captures a change of scope, not business growth (Celltrion 2023 Celltrion Healthcare merger, Samsung Biologics 2025 Samsung Bioepis spin-off).
Limitations: 연결 매출 · 재표시된 해는 최신 공시 값을 따른다 · 합병·분할이 있는 회사는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated revenue · restated years follow the latest filing · companies with a merger or spin-off mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
매출Revenue売上高Revenue index (FY2018 = 100) — Traditional pharma & holding
⚠ 규율: 합병·분할이 있는 회사는 지수가 사업 성장이 아니라 범위 변화를 담는다(셀트리온 2023 헬스케어 합병, 삼성바이오로직스 2025 에피스 분할).
⚠ Discipline: For companies with a merger or spin-off, the index captures a change of scope, not business growth (Celltrion 2023 Celltrion Healthcare merger, Samsung Biologics 2025 Samsung Bioepis spin-off).
Limitations: 연결 매출 · 재표시된 해는 최신 공시 값을 따른다 · 합병·분할이 있는 회사는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated revenue · restated years follow the latest filing · companies with a merger or spin-off mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익률Margin利益率Operating margin, latest FY vs. 3 years earlier
Limitations: 연결 영업이익 ÷ 연결 매출 · 음수 = 영업손실 · 결산이 다른 회사는 그 회사 최신 회계연도와 세 해 전.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated operating profit ÷ consolidated revenue · negative = operating loss · for companies with a different year-end, that company's latest fiscal year and three years earlier.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익Profit利益Net income and ROE, latest FY
회사
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
삼성바이오
n/a
0.20조
0.24조
0.39조
0.80조
0.86조
1.08조
1.78조
셀트리온
0.24조
0.30조
0.53조
0.60조
0.54조
0.54조
0.42조
1.03조
유한양행
0.06조
0.04조
0.19조
0.10조
0.09조
0.13조
0.06조
0.19조
대웅(지주)
0.03조
0.07조
0.12조
0.10조
0.12조
0.19조
0.07조
0.23조
GC녹십자
0.03조
-0.01조
0.09조
0.14조
0.07조
-0.02조
-0.04조
-0.03조
종근당
0.04조
0.05조
0.09조
0.04조
0.08조
0.21조
0.11조
0.08조
대웅제약
-0.02조
0.03조
0.02조
0.03조
0.04조
0.12조
0.02조
0.19조
한미약품
0.03조
0.06조
0.02조
0.08조
0.10조
0.17조
0.14조
0.19조
SD바이오센서
n/a
n/a
0.62조
1.06조
0.91조
-0.47조
-0.10조
-0.51조
SK바이오팜
n/a
-0.07조
-0.25조
0.06조
-0.14조
-0.04조
0.23조
0.25조
SK바이오사이언스
n/a
n/a
n/a
0.36조
0.12조
0.02조
-0.05조
-0.06조
한올바이오파마
0.00조
0.02조
0.02조
0.01조
0.00조
0.00조
-0.00조
-0.01조
연결 당기순이익(조원). 기준 변경·합병·분할 해는 비교 불가.
Company
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Samsung Bio
n/a
KRW 0.20trn
KRW 0.24trn
KRW 0.39trn
KRW 0.80trn
KRW 0.86trn
KRW 1.08trn
KRW 1.78trn
Celltrion
KRW 0.24trn
KRW 0.30trn
KRW 0.53trn
KRW 0.60trn
KRW 0.54trn
KRW 0.54trn
KRW 0.42trn
KRW 1.03trn
Yuhan
KRW 0.06trn
KRW 0.04trn
KRW 0.19trn
KRW 0.10trn
KRW 0.09trn
KRW 0.13trn
KRW 0.06trn
KRW 0.19trn
Daewoong (hold.)
KRW 0.03trn
KRW 0.07trn
KRW 0.12trn
KRW 0.10trn
KRW 0.12trn
KRW 0.19trn
KRW 0.07trn
KRW 0.23trn
GC Biopharma
KRW 0.03trn
KRW -0.01trn
KRW 0.09trn
KRW 0.14trn
KRW 0.07trn
KRW -0.02trn
KRW -0.04trn
KRW -0.03trn
Chong Kun Dang
KRW 0.04trn
KRW 0.05trn
KRW 0.09trn
KRW 0.04trn
KRW 0.08trn
KRW 0.21trn
KRW 0.11trn
KRW 0.08trn
Daewoong Pharm
KRW -0.02trn
KRW 0.03trn
KRW 0.02trn
KRW 0.03trn
KRW 0.04trn
KRW 0.12trn
KRW 0.02trn
KRW 0.19trn
Hanmi
KRW 0.03trn
KRW 0.06trn
KRW 0.02trn
KRW 0.08trn
KRW 0.10trn
KRW 0.17trn
KRW 0.14trn
KRW 0.19trn
SD Biosensor
n/a
n/a
KRW 0.62trn
KRW 1.06trn
KRW 0.91trn
KRW -0.47trn
KRW -0.10trn
KRW -0.51trn
SK Biopharm
n/a
KRW -0.07trn
KRW -0.25trn
KRW 0.06trn
KRW -0.14trn
KRW -0.04trn
KRW 0.23trn
KRW 0.25trn
SK Bioscience
n/a
n/a
n/a
KRW 0.36trn
KRW 0.12trn
KRW 0.02trn
KRW -0.05trn
KRW -0.06trn
HanAll
KRW 0.00trn
KRW 0.02trn
KRW 0.02trn
KRW 0.01trn
KRW 0.00trn
KRW 0.00trn
KRW -0.00trn
KRW -0.01trn
Consolidated net profit (KRW trn). Years with a change of basis, a merger or a spin-off are not comparable.
Limitations: 연결 당기순이익 · 기준 변경·합병·분할 해는 앞뒤 비교가 안 된다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated net profit · years with a change of basis, a merger or a spin-off cannot be compared with the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 連結当期純利益 · 基準変更・合併・分割の年は前後の比較ができない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
04
R&D 와 설비 — 돈을 어디에 쓰나R&D and plant — where the money goesR&Dと設備 — 資金をどこに使うか
R&DR&D spend as % of revenue and the share capitalized as development costs
⚠ 규율: 자산화 비중이 높으면 그해 영업이익이 그만큼 커진다 — 개발비는 뒤에 상각·손상으로 돌아온다.
⚠ Discipline: The higher the capitalised share, the larger that year's operating profit — development costs come back later as amortisation and impairment.
Limitations: 각 회사 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) ÷ 연구개발비용 계 · 표 서식이 다른 옛 해·일부 회사는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in each company's annual report · capitalised = development costs (intangible assets) ÷ total R&D expenses · older years and some companies with a different table format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
CapExCapex / revenue and free cash flow, latest FY
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Capex = cash spent on acquiring tangible and intangible assets (cash-flow statement) · FCF = operating cash flow − capex · leased assets and acquisitions are excluded.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
05
셀트리온 — 심층Celltrion — deep diveCelltrion — 深掘り
분기Quarterly四半期Celltrion: quarterly revenue and operating income
Limitations: 연결 분기 손익 · 4분기 = 연간 − 9개월 누계 · 합병 해(셀트리온 2023)는 앞뒤 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated quarterly income statement · Q4 = full year − nine-month cumulative · the merger year (Celltrion 2023) differs in scope from the years around it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 영업(잠정)실적(공정공시) — 외부감사인 검토 전 회사 발표값이다. 직전 분기·전년 동기 열은 회사가 같은 공시에 적은 비교값. 세전·순이익은 이번 공시에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Preliminary operating results (fair-disclosure filing) — company-announced figures before review by the external auditor. The prior-quarter and same-quarter-last-year columns are the comparatives the company gave in the same filing. Pre-tax and net profit are not in this filing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수출Exports輸出Celltrion: revenue vs. Korea immunological-product exports in measured doses, and the Hungary-bound part
합병 뒤(2024Q1~) 11분기: 매출과 수출 수준의 로그 상관 — 완제 전체(같은 분기) +0.27 · 헝가리행(전 분기) +0.35. 그 분기 전 자료로만 맞춘 전진 검증 6분기: 최선 '헝가리행 완제 · 전 분기' 평균 오차 13.1% vs 직전 분기 유지 14.5% · 이긴 분기 3/6 → 과반이 아니어서 우리 Fcst 를 내지 않는다. 헝가리행 비중(완제 수출 중): 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 YTD 39%.
After the merger (2024Q1 onwards), 11 quarters: log correlation of revenue with export levels — all dose-form exports (same quarter) +0.27 · Hungary-bound (previous quarter) +0.35. Forward test over 6 quarters, each fitted only on data before that quarter: best 'Hungary-bound dose-form exports · previous quarter', mean error 13.1% vs 14.5% for holding the previous quarter · quarters won 3/6 → not a majority, so we do not publish our Fcst. Hungary's share of dose-form exports: 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 YTD 39%.
⚠ 규율: 삼성바이오로직스(원료 수출 ≈ CDMO 매출)와 달리 이 세번엔 다른 회사 완제 출하가 섞이고, 셀트리온은 헝가리 100% 자회사(셀트리온헬스케어 헝가리 — 타법인 출자 현황)를 거쳐 판다 — 출하 시점과 매출 인식 시점이 어긋난다는 것은 가설이다. 2023Q4 이전 매출은 셀트리온헬스케어에 판 값이라 범위가 다르다.
⚠ Discipline: Unlike Samsung Biologics (drug-substance exports ≈ CDMO revenue), this tariff line also carries other companies' finished-product shipments, and Celltrion sells through a wholly owned subsidiary in Hungary (Celltrion Healthcare Hungary — investments in other companies) — that shipment timing and revenue recognition diverge is a hypothesis. Revenue before 2023Q4 was sales to Celltrion Healthcare, so its scope differs.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 완제 = 관세청 '면역물품(일정한 투여량으로 한 것·소매 포장)' 세번의 한국 전체 수출(모든 수출자), 원/달러 월평균 환산 · 헝가리행 = 최종 목적국 신고 기준 · 'P' = 잠정(외부감사인 검토 전) · 전진 검증 표본이 6분기뿐이다 · 합병(2023-12-28) 앞뒤 매출 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Dose-form = Korea's total exports (all exporters) under the customs tariff line for 'immunological products, put up in measured doses or for retail sale', converted at the monthly average KRW/USD rate · Hungary-bound = by declared country of final destination · 'P' = preliminary (before the external auditor's review) · the forward test covers only 6 quarters · revenue before and after the merger (2023-12-28) differs in scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
모델ModelモデルCelltrion: does export timing explain revenue? (one-quarter-ahead test, after the merger)
그 분기 전 자료로만 맞추고 그 분기를 맞힌 오차. 직전 분기 유지보다 평균 오차가 작고 검증 분기 과반에서 더 가까워야 Fcst 를 낸다 — 이번엔 못 미쳤다.
Errors from fitting only on data before each quarter and then predicting that quarter. We publish a Fcst only when the mean error is below that of holding the previous quarter and the model is closer in a majority of test quarters — this time it fell short.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 합병 뒤 11분기(마지막은 잠정)로 맞추고 6분기를 검증했다 · 표본이 작아 모델 간 차이는 우연일 수 있다 · 수출 계열은 한국 전체 합.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Fitted on 11 post-merger quarters (the last one preliminary) and tested on 6 · the sample is small, so differences between models may be chance · the export series are Korea-wide totals.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
목적국Destinations仕向国Korea dose-form immunological-product exports by destination (value share)
헝가리 비중: 2017 26% · 2018 29% · 2019 33% · 2020 9% · 2021 6% · 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 39%. 2024(합병 첫해)에 헝가리가 가장 컸다 — 유럽 거점으로 보내는 물량인지, 회사 몫인지는 이 자료로 못 가른다.
Hungary's share: 2017 26% · 2018 29% · 2019 33% · 2020 9% · 2021 6% · 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 39%. Hungary's share was largest in 2024 (the first full year after the merger) — whether these are volumes sent to a European hub or the company's own cannot be told from this data.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 최종 목적국 신고 기준 · 한국 전체 수출 · 전 기간 금액 상위 나라만 따로, 나머지는 Other · 마지막 해가 연중이면 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: By declared country of final destination · Korea-wide exports · only the countries with the largest value over the whole period are shown separately, the rest as Other · if the last year is incomplete it is year to date.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수익률Returns収益率Celltrion: ROIC with and without merger intangibles, ROE and incremental ROI (consolidated)
FY2025: ROIC 5.4% (무형자산 포함) vs 유형 영업자본 기준 18.5% · ROE 5.9%. 최근 4분기 ROIC 7.7% · 유형 기준 24.4% · ROE 9.0%. 합병 해(FY2023) 말 무형자산이 1.62조 → 13.34조로 11.71조 늘었다 — 같은 영업이익을 그만큼 큰 자본으로 나눈다. 유형 기준 ROIC 는 FY2020 31.6% → FY2025 18.5%.
FY2025: ROIC 5.4% (including intangibles) vs 18.5% on tangible operating capital · ROE 5.9%. Last four quarters: ROIC 7.7% · tangible basis 24.4% · ROE 9.0%. At the end of the merger year (FY2023) intangible assets went from KRW 1.62trn to KRW 13.34trn, up KRW 11.71trn — the same operating profit is divided by that much more capital. ROIC on a tangible basis: FY2020 31.6% → FY2025 18.5%.
⚠ 규율: * FY2023 = 합병 해: 그해 말 재무상태표엔 헬스케어가 들어가고 손익엔 없다 — 그해와 다음 해 평균 자본 지표는 범위가 섞인다. 증분 ROI 는 합병이 낀 창(FY2023~)이라 설비만의 수익률이 아니다.
⚠ Discipline: * FY2023 = merger year: Celltrion Healthcare is in that year-end balance sheet but not in the income statement — average-capital measures for that year and the next mix scopes. The incremental ROI window includes the merger (FY2023 onwards), so it is not a return on plant alone.
Limitations: 연결 · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산 + 매출채권 + 계약자산 + 재고 − 매입채무 − 계약부채) · 유형 기준 = 무형자산(합병으로 생긴 것 포함) 제외 · ROE = 지배주주 순이익 ÷ 평균 지배주주 자본 · 증분 ROI = 세후 영업이익 증가(세 해 전 대비) ÷ 그 사이 설비투자 · TTM 영업이익은 마지막 분기 잠정 포함.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets + receivables + contract assets + inventories − payables − contract liabilities) · tangible basis = excluding intangibles (including those created by the merger) · ROE = net profit attributable to owners of the parent ÷ average equity attributable to owners · incremental ROI = increase in after-tax operating profit (vs three years earlier) ÷ capex in between · TTM operating profit includes the last quarter's preliminary figure.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
투입·산출Inputs vs outputs投入と産出Celltrion: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2019–FY2025
FY
매출
영업이익
설비투자
유형자산
인원
인건비
1인당 매출
인건비/매출
판정
FY2019
—
—
—
—
—
—
5.3억
11.7%
—
FY2020
63.9%
88.3%
89.2%
2.5%
2.2%
22.8%
8.6억
8.8%
미달
FY2021
3.4%
5.3%
-40.6%
0.4%
2.3%
4.9%
8.7억
8.9%
미달
FY2022
19.5%
-14.5%
-3.0%
6.0%
2.5%
5.0%
10.1억
7.8%
미달
FY2023 *
-4.7%
0.7%
13.4%
20.6%
11.8%
13.4%
8.6억
9.3%
미달
FY2024 *
63.4%
-24.5%
-5.7%
2.5%
14.7%
36.9%
12.3억
7.8%
미달
FY2025
17.0%
137.5%
-0.5%
36.8%
8.7%
16.0%
13.2억
7.7%
미달
전년 대비 증가율 · 매출·영업이익·설비투자·유형자산 = 연결 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신, 기간제 포함) · * = 합병이 낀 해
FY
Revenue
Operating profit
Capex
PP&E
Headcount
Payroll
Revenue per head
Payroll / revenue
Verdict
FY2019
—
—
—
—
—
—
5.3 KRW 100mn
11.7%
—
FY2020
63.9%
88.3%
89.2%
2.5%
2.2%
22.8%
8.6 KRW 100mn
8.8%
fail
FY2021
3.4%
5.3%
-40.6%
0.4%
2.3%
4.9%
8.7 KRW 100mn
8.9%
fail
FY2022
19.5%
-14.5%
-3.0%
6.0%
2.5%
5.0%
10.1 KRW 100mn
7.8%
fail
FY2023 *
-4.7%
0.7%
13.4%
20.6%
11.8%
13.4%
8.6 KRW 100mn
9.3%
fail
FY2024 *
63.4%
-24.5%
-5.7%
2.5%
14.7%
36.9%
12.3 KRW 100mn
7.8%
fail
FY2025
17.0%
137.5%
-0.5%
36.8%
8.7%
16.0%
13.2 KRW 100mn
7.7%
fail
Year-on-year growth · revenue, operating profit, capex and PP&E = consolidated · headcount and payroll = 'employee status' in the annual report (the company itself, fixed-term staff included) · * = year that includes a merger
연평균(FY2019→FY2025): 매출 24.3% · 영업이익 20.5% · 유형자산 10.7% · 인원 6.9% · 인건비 16.0% · 1인당 매출 5.3억 → 13.2억. 해마다 판정: 통과 없음 · 미달 2020, 2021, 2022, 2023, 2024, 2025. 합병 전 매출은 셀트리온헬스케어에 판 값이라 연평균 매출 증가에 범위 변화가 섞인다.
Average annual growth (FY2019→FY2025): revenue 24.3% · operating profit 20.5% · PP&E 10.7% · headcount 6.9% · payroll 16.0% · revenue per head 5.3 KRW 100mn → 13.2 KRW 100mn. Year-by-year verdict: pass none · fail 2020, 2021, 2022, 2023, 2024, 2025. Pre-merger revenue was sales to Celltrion Healthcare, so the average revenue growth mixes in a change of scope.
⚠ 규율: 판정 = 그해 매출·영업이익 증가율(작은 쪽)이 설비투자·유형자산·인원·인건비 증가율(큰 쪽)을 넘었나 — 엄격한 잣대다. 표에서 어느 투입이 막았는지 본다.
⚠ Discipline: Verdict = did that year's growth in revenue and operating profit (the smaller of the two) exceed the growth in capex, PP&E, headcount and payroll (the largest)? It is a strict test. The table shows which input held it back.
Limitations: 매출·영업이익·설비투자·유형자산 = 연결 재무제표 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신만 — 해외 판매법인 인원은 빠진다) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 합병이 낀 해는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Revenue, operating profit, capex and PP&E = consolidated financial statements · headcount and payroll = 'employee status' in the annual report (the company itself only — staff at overseas sales subsidiaries are excluded) · average annual = compound growth between the first and last year · years that include a merger mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
밸류ValuationバリュエーションCelltrion: trailing P/E and P/B on KRX market cap (treasury shares excluded)
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX market cap (all listed shares) × (1 − treasury-share ratio) · net profit = net profit attributable to owners from the quarterly reports (the last quarter is left out because the preliminary filing has no net profit) · after-tax operating profit = operating profit × (1 − FY effective tax rate).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분 사슬Ownership chain持株チェーンCelltrion: economic interest of the controlling family vs. voting control (look-through)
첫 단계 보유자
관계
지분율
자기주식 뺀 몫
그 경로로 가족에게
경로
(주)셀트리온홀딩스
본인
25.85%
26.30%
0.00%
비상장 법인(위 확인 안 함)
서정진
최대주주
4.20%
4.27%
4.27%
가족
(주)셀트리온스킨큐어
계열회사
2.18%
2.22%
0.00%
비상장 법인(위 확인 안 함)
경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준
First-tier holder
Relation
Stake
Share ex-treasury
To the family via this path
Path
Selteurionholdingseu
self
25.85%
26.30%
0.00%
unlisted corporate (owners not checked)
Seo Jeongjin
largest shareholder
4.20%
4.27%
4.27%
family
Selteurionseukinkyueo
affiliate
2.18%
2.22%
0.00%
unlisted corporate (owners not checked)
Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1
최대주주 측 32.6% · 자기주식 1.7% → 의결권 기준 33.2%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 4.4% (서정진 4.3% · 박준성 0.1% · 이종관 0.0% · 이명숙 0.0% · 박상현 0.0%) → 지배-소유 괴리 28.8%p. 위를 모르는 비상장 법인 (주)셀트리온홀딩스, (주)셀트리온스킨큐어 몫 28.5%는 그 주주가 Raw Data 에 없어 가족 몫에 넣지 못했다(확인 안 함) — 가족 몫은 하한이다. 추이: 2019Q1 최대주주 본인 20.07% · 측 합 22.74% → 2026H1 25.85% · 32.69%. 이 회사가 가진 상장 지분 시가 0.97조 = 자기주식 뺀 시총의 2%.
Largest-shareholder group 32.6% · treasury shares 1.7% → 33.2% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 4.4% (Seo Jeongjin 4.3% · Bak Junseong 0.1% · I Jonggwan 0.0% · I Myeongsuk 0.0% · Bak Sanghyeon 0.0%) → control–ownership wedge 28.8pp. The 28.5% held by unlisted corporates whose owners are unknown (Selteurionholdingseu, Selteurionseukinkyueo) could not be added to the family's share because their shareholders are not in the Raw Data (not checked) — the family share is a lower bound. Trend: 2019Q1 largest shareholder alone 20.07% · group total 22.74% → 2026H1 25.85% · 32.69%. Market value of the listed stakes this company owns: KRW 0.97trn = 2% of its market cap excluding treasury shares.
筆頭株主側32.6% · 自己株式1.7% → 議決権ベース33.2%。支配家族(チェーン上のどの表でも本人・親族・特別関係者とされた人)のこの会社の利益に対する経済的持分4.4%(Seo Jeongjin 4.3% · Bak Junseong 0.1% · I Jonggwan 0.0% · I Myeongsuk 0.0% · Bak Sanghyeon 0.0%) → 支配と所有の乖離28.8%pt。上位の株主が不明な非上場法人(Selteurionholdingseu、Selteurionseukinkyueo)の持分28.5%は、その株主がRaw Dataにないため家族の持分に入れられなかった(未確認) — 家族の持分は下限である。推移:2019Q1 筆頭株主本人20.07% · 側の合計22.74% → 2026H1 25.85% · 32.69%。この会社が保有する上場株式の時価0.97兆ウォン = 自己株式を除いた時価総額の2%。
⚠ 규율: 셀트리온홀딩스 지분이 늘어난 데에는 자기주식 소각도 있다 — 소각은 발행주식을 줄여 같은 주식 수로도 지분율을 올린다(최근 소각: 2024FY 3,429,737주; 2025FY 4,970,950주; 2026H1 9,598,977주).
⚠ Discipline: Part of the rise in Celltrion Holdings' stake comes from treasury-share cancellation — cancellation reduces the shares in issue, so the same number of shares gives a higher percentage (recent cancellations: 2024FY 3,429,737 shares; 2025FY 4,970,950 shares; 2026H1 9,598,977 shares).
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
품목Product lines品目Celltrion: sales by business line / product (annual report table)
⚠ Discipline: Only the three periods in the table — if the company restates, earlier periods change.
⚠ 規律:表の3期分のみ — 会社が再表示すると前の期の値が変わる。
Source: DART, Financial Supervisory Service.
Limitations: 최신 사업보고서 '매출실적' 표의 세 기수 · 라벨은 회사 표기 · 회사가 재표시하면 앞 기수 값이 바뀐다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The three periods in the 'sales results' table of the latest annual report · labels follow the company's categories · if the company restates, earlier periods change.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
R&DCelltrion: R&D spend, capitalized development costs and R&D-to-sales
FY2018: R&D 2,936억 (매출 대비 34.06%), 자산화 1,980억 (67.5%) · FY2019: R&D 3,052억 (매출 대비 31.09%), 자산화 1,888억 (61.9%) · FY2020: R&D 3,750억 (매출 대비 22.19%), 자산화 2,024억 (54.0%) · FY2021: R&D 4,304억 (매출 대비 20.82%), 자산화 2,722억 (63.2%) · FY2022: R&D 4,124억 (매출 대비 18.05%), 자산화 2,726억 (66.1%) · FY2023: R&D 3,427억 (매출 대비 15.75%), 자산화 1,816억 (53.0%) · FY2024: R&D 4,347억 (매출 대비 12.22%), 자산화 2,202억 (50.7%) · FY2025: R&D 4,824억 (매출 대비 11.59%), 자산화 2,717억 (56.3%).
Limitations: 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) · 서식이 다른 옛 해는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in the annual report · capitalised = development costs (intangible assets) · older years with a different format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
운전자본Working capital運転資本Celltrion: inventory and receivable days, net debt
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
특수관계자Related parties関連当事者Celltrion: sales to related parties (from the related-party note)
⚠ 규율: 표의 첫 값 열(매출/수익)을 읽었다 — 열 정의는 연도별 헤더 참조. 셀트리온은 2023년 말 헬스케어 합병으로 이 매출이 내부거래로 사라졌다.
⚠ Discipline: We read the first value column of the table (sales/revenue) — see each year's header for the column definition. At Celltrion these sales became intra-group transactions after the Celltrion Healthcare merger at the end of 2023.
Limitations: 특수관계자 주석 표의 첫 값 열 — 열 정의는 해마다 헤더를 따른다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: First value column of the related-party note table — the column definition follows each year's header.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 関連当事者注記の表の最初の値の列 — 列の定義は年ごとのヘッダーに従う。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분Ownership持株Celltrion: largest shareholder and treasury shares by quarter
⚠ Discipline: Dividends received by major shareholders and related parties FY2025: KRW 45444.0 mn (prior year KRW 30350.0 mn). Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図Celltrion: cross-shareholding map, FY2022 (7 affiliates in group '셀트리온')Celltrion: cross-shareholding map, FY2022 (7 affiliates in group 'Celltrion')Celltrion: cross-shareholding map, FY2022 (7 affiliates in group 'Celltrion')
(주)셀트리온 → (주)셀트리온제약 54.85% · (주)셀트리온홀딩스 → (주)셀트리온 20.04% · (주)셀트리온스킨큐어 → (주)셀트리온 2.11%. 해외 계열 출자 0건.
⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).
⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図Celltrion: cross-shareholding map, FY2025 (9 affiliates in group '셀트리온')Celltrion: cross-shareholding map, FY2025 (9 affiliates in group 'Celltrion')Celltrion: cross-shareholding map, FY2025 (9 affiliates in group 'Celltrion')
⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).
⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
설비Plant設備Celltrion: capacity, output and utilization (annual report tables)
표
항목
당기
전기
전전기
capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장
133.0
133.0
capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장
82.0
82.0
capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장
98.0
98.0
capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계
313.0
313.0
Table
Item
Current period
Prior period
Two periods ago
Capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장
133.0
133.0
Capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장
82.0
82.0
Capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장
98.0
98.0
Capacity
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계
313.0
313.0
表
項目
当期
前期
前々期
生産能力
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장
133.0
133.0
生産能力
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장
82.0
82.0
生産能力
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장
98.0
98.0
生産能力
의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계
313.0
313.0
생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).
Capacity, output and utilisation tables (units as in each table: batches etc.).
生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。
Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
구조Structure構造Celltrion: structural events, pipeline and licenses (annual report text)
구분
품목
적응증
연구시작일
현재 진행 단계
비고
바이오
바이오시밀러
CT-P44
Multiple Myeloma
2019년
3상 진행 중
CT-P51
Non Small Cell Lung Cancer
2019년
3상 진행 중
-
-
CT-P53
Multiple Sclerosis
2021년
3상 진행 중
-
-
CT-P55
Plaque Psoriasis
2021년
3상 진행 중
-
-
신약
CT-P27
Flu
2009년
2상 완료
-
CT-P70
Non-small cell lung cancer
2025년
1상 진행 중
-
-
CT-P71
Urothelial Cancer
2025년
1상 진행 중
-
-
CT-P72
Gastric cancer
2025년
1상 진행 중
-
-
CT-P73
Cervical cancer
2025년
1상 진행 중
-
-
화학합성
신약
CT-G20
HCM(비후성 심근증) 치료제
2018년
1상 완료
사업결합: 38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="
Business combination: 38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="
企業結合:38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="
⚠ 규율: 파이프라인 10건 · 라이선스 아웃 0건 · 인 13건(원문 표 기준).
⚠ Discipline: Pipeline 10 · licence-out 0 · licence-in 13 (as in the original tables).
⚠ 規律:パイプライン10件 · ライセンスアウト0件 · イン13件(原文の表ベース)。
Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
06
삼성바이오 — 심층Samsung Bio — deep diveSamsung Bio — 深掘り
분기Quarterly四半期Samsung Bio: quarterly revenue and operating income (separate = CDMO; last quarter preliminary)
최근 분기 2026Q3(잠정): 매출 1.49조 · 영업이익 0.64조(이익률 43.0%).
Limitations: 별도 재무제표(분할 전에도 CDMO 만) + 'P' 표시 분기는 영업(잠정)실적 공정공시(연결, 외부감사인 검토 전) — 분할 뒤엔 연결 ≈ 별도. 4분기 = 연간 − 9개월 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements (CDMO only, even before the spin-off) + quarters marked 'P' are preliminary operating results from fair-disclosure filings (consolidated, before the external auditor's review) — after the spin-off, consolidated ≈ separate. Q4 = full year − nine-month cumulative.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
KRW 100mn · consolidated · as in the company's filing table (growth rates recalculated)
項目
2026Q3 速報
前四半期
QoQ
前年同期
YoY
累計
累計 YoY
売上高
14,903億ウォン
13,209億ウォン
+12.8%
12,575億ウォン
+18.5%
40,684億ウォン
+24.4%
営業利益
6,401億ウォン
5,864億ウォン
+9.2%
6,335億ウォン
+1.0%
18,073億ウォン
+17.3%
税引前利益
5,320億ウォン
5,846億ウォン
-9.0%
6,626億ウォン
-19.7%
17,573億ウォン
+13.8%
当期純利益
3,911億ウォン
4,307億ウォン
-9.2%
4,964億ウォン
-21.2%
12,910億ウォン
+11.2%
億ウォン · 連結 · 会社開示の表のまま(増減率は再計算)
2026Q3 잠정: 매출 14,903억 · 영업이익 6,401억(이익률 43.0%) · 세전이익 5,320억 · 순이익 3,911억. 세전이익이 영업이익보다 1,081억 작다 — 잠정 공시에는 영업외 내역이 없어 원인은 분기보고서에서 본다. 지난 잠정과 확정의 차이: 2026Q2 매출 잠정 13,209억 vs 확정 13,209억 · 영업이익 5,864억 vs 5,864억.
2026Q3 preliminary: revenue 14,903 KRW 100mn · operating profit 6,401 KRW 100mn (margin 43.0%) · pre-tax profit 5,320 KRW 100mn · net profit 3,911 KRW 100mn. Pre-tax profit is 1,081 KRW 100mn lower than operating profit — the preliminary filing has no breakdown of non-operating items, so the cause has to be read from the quarterly report. Past preliminary vs final: 2026Q2 revenue preliminary 13,209 KRW 100mn vs final 13,209 KRW 100mn · operating profit 5,864 KRW 100mn vs 5,864 KRW 100mn.
2026Q3速報:売上高14,903億ウォン · 営業利益6,401億ウォン(利益率43.0%) · 税引前利益5,320億ウォン · 純利益3,911億ウォン。税引前利益が営業利益より1,081億ウォン小さい — 速報には営業外の内訳がないため、原因は四半期報告書で見る。過去の速報と確定の差:2026Q2 売上高 速報13,209億ウォン vs 確定13,209億ウォン · 営業利益5,864億ウォン vs 5,864億ウォン。
⚠ 규율: 잠정치는 회사 발표값(외부감사인 검토 전) — 분기보고서가 나오면 그 값으로 바꾼다.
⚠ Discipline: Preliminary figures are company announcements (before the external auditor's review) — they are replaced once the quarterly report is out.
Limitations: 영업(잠정)실적(공정공시) — 외부감사인 검토 전 회사 발표값이다. 직전 분기·전년 동기 열은 회사가 같은 공시에 적은 비교값(에피스 분할 재표시 반영).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Preliminary operating results (fair-disclosure filing) — company-announced figures before review by the external auditor. The prior-quarter and same-quarter-last-year columns are the comparatives the company gave in the same filing (restated for the Samsung Bioepis spin-off).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수출Exports輸出Samsung Bio: CDMO revenue vs. Korea biologic drug-substance exports, with Adrenalin Baby Fcst
원료(DS) 수출 = 관세청 '면역물품(일정한 투여량으로 하지 않은 것)' 두 세번의 한국 전체 수출(원화 환산). 수준은 같이 간다(로그 상관 +0.90). 분기 매출을 가장 잘 맞힌 것은 '한·두 분기 앞 수출 평균'(전진 평균 오차 6.0% vs 직전 분기 유지 6.6%, 7분기 검증) — 탄력성 0.71. 2026Q4 우리 Fcst: 매출 14,576억 (±6%) — 영업이익률이 직전 분기(43.0%)와 같다고 두면 영업이익 6,260억(가정).
Drug-substance (DS) exports = Korea's total exports (converted to KRW) under the two customs tariff lines for 'immunological products, not put up in measured doses'. The levels move together (log correlation +0.90). Quarterly revenue was best predicted by 'average of exports one and two quarters earlier' (forward mean error 6.0% vs 6.6% for holding the previous quarter, tested on 7 quarters) — elasticity 0.71. 2026Q4 our Fcst: revenue 14,576 KRW 100mn (±6%) — if the operating margin stays at the previous quarter's (43.0%), operating profit would be 6,260 KRW 100mn (assumption).
原薬(DS)輸出 = 関税庁「免疫物品(一定の投与量にしていないもの)」2税番の韓国全体の輸出(ウォン換算)。水準は連動する(対数相関+0.90)。四半期売上高を最もよく当てたのは「1・2四半期前の輸出平均」(フォワード平均誤差6.0% vs 前四半期据え置き6.6%、7四半期で検証) — 弾性値0.71。2026Q4 当サイトFcst:売上高14,576億ウォン(±6%) — 営業利益率が前四半期(43.0%)と同じとすると営業利益6,260億ウォン(仮定)。
⚠ 규율: 같은 세번에 다른 회사 출하가 섞이고, 통관가(제품 가치)와 CDMO 매출(위탁 생산료)은 기준이 다르다 — 회사 몫이 아니라 탄력성으로만 읽는다.
⚠ Discipline: The same tariff lines carry other companies' shipments, and customs value (product value) and CDMO revenue (contract-manufacturing fees) are on different bases — read this only as an elasticity, not the company's share.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 원료 세번은 HS 2022 개정으로 생겨 2022년부터 있다. 관세청 수출은 한국 전체(모든 수출자) 합이고 원/달러 월평균으로 환산했다. 우리 Fcst 는 수출이 매출보다 한두 분기 앞선다는 과거 관계를 쓴 추정이지 회사 가이던스나 컨센서스가 아니다. 검증 분기 수가 적다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: The drug-substance tariff lines were created in the HS 2022 revision, so they exist only from 2022. Customs exports are Korea-wide totals (all exporters), converted at the monthly average KRW/USD rate. Our Fcst is an estimate using the past relationship in which exports lead revenue by one or two quarters — it is neither company guidance nor consensus. Few quarters have been tested.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
모델ModelモデルSamsung Bio: which export timing explains revenue (one-quarter-ahead test)
수출 시점
평균 |오차|
직전 분기 유지
검증 분기
마지막 오차
탄력성
같은 분기 수출
12.5%
9.2%
9
2026Q3 -24.9%
0.67
한 분기 앞 수출
9.7%
7.3%
8
2026Q3 13.4%
0.67
같은·앞 분기 수출 평균
8.9%
7.3%
8
2026Q3 -6.2%
0.74
한·두 분기 앞 수출 평균
6.0%
6.6%
7
2026Q3 7.4%
0.71
Export timing
Mean |error|
Hold previous quarter
Test quarters
Last error
Elasticity
exports in the same quarter
12.5%
9.2%
9
2026Q3 -24.9%
0.67
exports one quarter earlier
9.7%
7.3%
8
2026Q3 13.4%
0.67
average of same- and previous-quarter exports
8.9%
7.3%
8
2026Q3 -6.2%
0.74
average of exports one and two quarters earlier
6.0%
6.6%
7
2026Q3 7.4%
0.71
輸出の時点
平均|誤差|
前四半期据え置き
検証四半期
最後の誤差
弾性値
同じ四半期の輸出
12.5%
9.2%
9
2026Q3 -24.9%
0.67
1四半期前の輸出
9.7%
7.3%
8
2026Q3 13.4%
0.67
同じ四半期と前四半期の輸出平均
8.9%
7.3%
8
2026Q3 -6.2%
0.74
1・2四半期前の輸出平均
6.0%
6.6%
7
2026Q3 7.4%
0.71
그 분기 전 자료로만 맞추고 그 분기를 맞힌 오차. 고른 모델: 한·두 분기 앞 수출 평균. 마지막 검증 분기(2026Q3)는 오늘 나온 잠정 매출로 채점했다.
Errors from fitting only on data before each quarter and then predicting that quarter. Model chosen: average of exports one and two quarters earlier. The last test quarter (2026Q3) was scored against the preliminary revenue released today.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 검증 분기가 7~9개뿐이라 모델 간 차이가 우연일 수 있다. 수출이 매출을 앞선다는 것은 이 표본의 관계이지 출하·매출 인식 시점을 확인한 것이 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Only 7–9 test quarters, so differences between models may be chance. That exports lead revenue is a relationship in this sample, not a confirmed timing of shipments and revenue recognition.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
목적국Destinations仕向国Korea biologic drug-substance exports by destination (value share)
회사 지역별 매출(사업보고서)은 유럽 > 미국 순이다 — 원료 수출 목적국도 스위스·네덜란드·독일 등 유럽 비중이 크다. 같은 방향인지 보는 것이지 회사 몫이 아니다.
The company's revenue by region (annual report) ranks Europe ahead of the United States — the destinations of drug-substance exports also lean towards Europe (Switzerland, the Netherlands, Germany and others). This checks the direction, not the company's share.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 원료 세번은 HS 2022 개정으로 생겨 2022년부터 · 최종 목적국 신고 기준 · 한국 전체 수출 · 전 기간 금액 상위 나라만 따로, 나머지는 Other · 마지막 해가 연중이면 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: The drug-substance tariff lines exist only from 2022 (created in the HS 2022 revision) · by declared country of final destination · Korea-wide exports · only the countries with the largest value over the whole period are shown separately, the rest as Other · if the last year is incomplete it is year to date.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
밸류ValuationバリュエーションSamsung Bio: trailing P/E and P/B on KRX market cap
Market cap on 2026-11-10 KRW 67.96trn · net profit over the last four quarters (2025Q4–2026Q3) 17,585 KRW 100mn → P/E 38.6x · equity attributable to owners (2026Q2) KRW 8.36trn → P/B 8.13x.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: 최근 4분기 순이익 = 별도 분기 + 마지막 분기 잠정(연결) — 분할 뒤엔 둘이 거의 같다. 자본은 마지막 분기보고서 연결 지배주주 자본. 무배당.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: Net profit over the last four quarters = separate quarters + the last quarter's preliminary figure (consolidated) — after the spin-off the two are almost the same. Equity is consolidated equity attributable to owners from the latest quarterly report. No dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수익률Returns収益率Samsung Bio: ROE, ROIC and incremental return on capex (separate = CDMO)
FY2025: ROIC 21.1% · ROE 19.0% · 증분 ROI 26.1% — 최근 4분기(2025Q4~2026Q3) ROIC 21.6% · ROE 22.3%. ROE 가 ROIC 보다 낮았던 해는 자본에 에피스 지분·현금이 같이 들어 있던 때다(2025-11 분할로 빠짐). 증분 ROI 는 FY2022 정점(84.3%) 뒤 FY2025 26.1%로 내려왔다 — 그 사이 유형자산 증가율이 매출 증가율을 넘은 해가 있다(FY2024 유형자산 42.5% vs 매출 19.0%).
FY2025: ROIC 21.1% · ROE 19.0% · incremental ROI 26.1% — last four quarters (2025Q4–2026Q3) ROIC 21.6% · ROE 22.3%. The years when ROE was below ROIC were when equity still included the Samsung Bioepis stake and cash (removed by the 2025-11 spin-off). Incremental ROI came down from its FY2022 peak (84.3%) to FY2025 26.1% — in between there was a year when PP&E growth outpaced revenue growth (FY2024 PP&E 42.5% vs revenue 19.0%).
⚠ 규율: 투하자본은 영업 쪽(유형·무형자산 + 운전자본) — 자본·부채 쪽 계산은 2017 부채 계정이 Raw Data 에 없어 쓰지 않았다.
⚠ Discipline: Invested capital is on the operating side (tangible and intangible assets + working capital) — the financing-side calculation was not used because the 2017 liability accounts are not in the Raw Data.
Limitations: 별도 재무제표(CDMO) · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산 + 매출채권 + 계약자산 + 재고 − 매입채무 − 계약부채) · ROE = 순이익 ÷ 평균 자본 · 증분 ROI = 세후 영업이익 증가(그해 vs 세 해 전) ÷ 그 앞 세 해 설비투자 누계 · TTM 은 마지막 분기 잠정 포함.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements (CDMO) · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets + receivables + contract assets + inventories − payables − contract liabilities) · ROE = net profit ÷ average equity · incremental ROI = increase in after-tax operating profit (that year vs three years earlier) ÷ cumulative capex over the three preceding years · TTM includes the last quarter's preliminary figure.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
설비→매출Capex → revenue設備→売上高Samsung Bio: capex vs. revenue increase and operating income (separate)
설비투자와 매출 증가의 연간 상관: 0년 시차 +0.77(n 8) · 1년 시차 +0.56(n 8) · 2년 시차 +0.34(n 7) · 3년 시차 +0.58(n 6). 같은 해 상관이 가장 높다 — 확장기에는 짓는 것과 파는 것이 함께 는다. 표본이 짧아 시차를 확정하지 못한다.
Annual correlation between capex and revenue growth: 0-year lag +0.77 (n 8) · 1-year lag +0.56 (n 8) · 2-year lag +0.34 (n 7) · 3-year lag +0.58 (n 6). The same-year correlation is the highest — in an expansion phase building and selling rise together. The sample is short, so the lag cannot be pinned down.
Limitations: 별도 · 설비투자 = 유형·무형자산 취득 현금 · 연간 상관은 표본이 작고(6~8년) 확장 국면이 겹쳐 인과를 말하지 않는다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Separate · capex = cash spent on acquiring tangible and intangible assets · the annual correlations rest on a small sample (6–8 years) during overlapping expansion phases and say nothing about causation.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
투입·산출Inputs vs outputs投入と産出Samsung Bio: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2017–FY2025
FY
매출
영업이익
설비투자
유형자산
인원
인건비
1인당 매출
인건비/매출
판정
FY2017
—
—
—
—
—
—
2억
29.0%
—
FY2018
15.3%
-15.6%
-43.6%
13.5%
9.4%
3.2%
2억
26.0%
미달
FY2019
30.9%
64.8%
-36.3%
-0.9%
11.6%
38.1%
3억
27.4%
미달
FY2020
66.0%
218.9%
-19.0%
1.8%
11.6%
18.7%
4억
19.6%
통과
FY2021
34.6%
83.4%
184.7%
27.0%
37.2%
23.1%
4억
17.9%
미달
FY2022
55.4%
80.4%
129.7%
40.0%
14.5%
40.4%
5억
16.2%
미달
FY2023
20.6%
24.4%
4.3%
14.9%
-2.4%
14.7%
7억
15.4%
통과
FY2024
19.0%
9.7%
32.2%
42.5%
13.2%
13.4%
7억
14.6%
미달
FY2025
30.3%
56.5%
4.8%
19.4%
8.9%
19.1%
8억
13.4%
통과
전년 대비 증가율 · 인원·인건비 = 사업보고서 '직원 등의 현황'(별도, 기간제 포함) · 1인당 매출 = 매출 ÷ 연말 인원
FY
Revenue
Operating profit
Capex
PP&E
Headcount
Payroll
Revenue per head
Payroll / revenue
Verdict
FY2017
—
—
—
—
—
—
2 KRW 100mn
29.0%
—
FY2018
15.3%
-15.6%
-43.6%
13.5%
9.4%
3.2%
2 KRW 100mn
26.0%
fail
FY2019
30.9%
64.8%
-36.3%
-0.9%
11.6%
38.1%
3 KRW 100mn
27.4%
fail
FY2020
66.0%
218.9%
-19.0%
1.8%
11.6%
18.7%
4 KRW 100mn
19.6%
pass
FY2021
34.6%
83.4%
184.7%
27.0%
37.2%
23.1%
4 KRW 100mn
17.9%
fail
FY2022
55.4%
80.4%
129.7%
40.0%
14.5%
40.4%
5 KRW 100mn
16.2%
fail
FY2023
20.6%
24.4%
4.3%
14.9%
-2.4%
14.7%
7 KRW 100mn
15.4%
pass
FY2024
19.0%
9.7%
32.2%
42.5%
13.2%
13.4%
7 KRW 100mn
14.6%
fail
FY2025
30.3%
56.5%
4.8%
19.4%
8.9%
19.1%
8 KRW 100mn
13.4%
pass
Year-on-year growth · headcount and payroll = 'employee status' in the annual report (separate, fixed-term staff included) · revenue per head = revenue ÷ year-end headcount
⚠ 규율: 판정 = 그해 매출·영업이익 증가율이 설비투자·유형자산·인원·인건비 증가율을 모두 넘었나. 공장을 짓는 해(설비 먼저)는 미달이 정상이다 — 몇 해 뒤 통과로 돌아오는지가 볼 점.
⚠ Discipline: Verdict = did that year's revenue and operating-profit growth exceed the growth in capex, PP&E, headcount and payroll on every count? In years when plants are being built (plant first) a fail is normal — what matters is whether it turns into a pass a few years later.
Limitations: 별도 재무제표 + 사업보고서 '직원 등의 현황'(연말 인원·연간 급여 총액, 기간제 포함) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 유형자산은 장부 순액(감가상각 뒤).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements + 'employee status' in the annual report (year-end headcount and total annual pay, fixed-term staff included) · average annual = compound growth between the first and last year · PP&E is the net book amount (after depreciation).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분 사슬Ownership chain持株チェーンSamsung Bio: economic interest of the controlling family vs. voting control (look-through)
첫 단계 보유자
관계
지분율
자기주식 뺀 몫
그 경로로 가족에게
경로
삼성물산
최대주주
43.06%
43.11%
15.39%
상장사(사슬 위로)
삼성전자
계열회사
31.22%
31.25%
2.73%
상장사(사슬 위로)
경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준
First-tier holder
Relation
Stake
Share ex-treasury
To the family via this path
Path
Samsung C&T
largest shareholder
43.06%
43.11%
15.39%
listed company (chain continues up)
Samsung Electronics
affiliate
31.22%
31.25%
2.73%
listed company (chain continues up)
Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1
최대주주 측 74.3% · 자기주식 0.1% → 의결권 기준 74.4%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 18.1% (이재용 10.7% · 이서현 3.5% · 이부진 3.3% · 홍라희 0.4% · 이유정 0.2%) → 지배-소유 괴리 56.3%p. 추이: 2019Q1 최대주주 본인 43.44% · 측 합 75.09% → 2026H1 43.06% · 74.30%.
Largest-shareholder group 74.3% · treasury shares 0.1% → 74.4% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 18.1% (I Jaeyong 10.7% · I Seohyeon 3.5% · I Bujin 3.3% · Hong Rahui 0.4% · I Yujeong 0.2%) → control–ownership wedge 56.3pp. Trend: 2019Q1 largest shareholder alone 43.44% · group total 75.09% → 2026H1 43.06% · 74.30%.
筆頭株主側74.3% · 自己株式0.1% → 議決権ベース74.4%。支配家族(チェーン上のどの表でも本人・親族・特別関係者とされた人)のこの会社の利益に対する経済的持分18.1%(I Jaeyong 10.7% · I Seohyeon 3.5% · I Bujin 3.3% · Hong Rahui 0.4% · I Yujeong 0.2%) → 支配と所有の乖離56.3%pt。推移:2019Q1 筆頭株主本人43.44% · 側の合計75.09% → 2026H1 43.06% · 74.30%。
⚠ 규율: 삼성물산·삼성생명은 보유 상장 지분 시가가 자기 시총보다 크다(물산 217% · 생명 235%) — 생명은 보험사라 보유 주식이 보험부채와 함께 있어 지주 할인과 같은 잣대로 읽지 않는다.
⚠ Discipline: Samsung C&T and Samsung Life hold listed stakes worth more than their own market caps (Samsung C&T 217% · Samsung Life 235%) — Samsung Life is an insurer, so its shareholdings sit alongside insurance liabilities and are not read on the same yardstick as a holding-company discount.
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
품목Product lines品目Samsung Bio: sales by business line / product (annual report table)
⚠ Discipline: Only the three periods in the table — if the company restates, earlier periods change.
⚠ 規律:表の3期分のみ — 会社が再表示すると前の期の値が変わる。
Source: DART, Financial Supervisory Service.
Limitations: 최신 사업보고서 '매출실적' 표의 세 기수 · 라벨은 회사 표기 · 회사가 재표시하면 앞 기수 값이 바뀐다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The three periods in the 'sales results' table of the latest annual report · labels follow the company's categories · if the company restates, earlier periods change.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
R&DSamsung Bio: R&D spend, capitalized development costs and R&D-to-sales
FY2019: R&D 485억 (매출 대비 6.9%), 자산화 n/a (n/a) · FY2020: R&D 786억 (매출 대비 6.7%), 자산화 n/a (n/a) · FY2021: R&D 919억 (매출 대비 5.9%), 자산화 n/a (n/a) · FY2022: R&D 2,682억 (매출 대비 8.9%), 자산화 687억 (25.6%) · FY2023: R&D 3,253억 (매출 대비 8.8%), 자산화 671억 (20.6%) · FY2024: R&D 3,929억 (매출 대비 8.6%), 자산화 609억 (15.5%) · FY2025: R&D 1,674억 (매출 대비 3.7%), 자산화 n/a (n/a).
Limitations: 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) · 서식이 다른 옛 해는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in the annual report · capitalised = development costs (intangible assets) · older years with a different format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
운전자본Working capital運転資本Samsung Bio: inventory and receivable days, net debt
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
특수관계자Related parties関連当事者Samsung Bio: sales to related parties (from the related-party note)
⚠ 규율: 표의 첫 값 열(매출/수익)을 읽었다 — 열 정의는 연도별 헤더 참조. 셀트리온은 2023년 말 헬스케어 합병으로 이 매출이 내부거래로 사라졌다.
⚠ Discipline: We read the first value column of the table (sales/revenue) — see each year's header for the column definition. At Celltrion these sales became intra-group transactions after the Celltrion Healthcare merger at the end of 2023.
Limitations: 특수관계자 주석 표의 첫 값 열 — 열 정의는 해마다 헤더를 따른다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: First value column of the related-party note table — the column definition follows each year's header.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 関連当事者注記の表の最初の値の列 — 列の定義は年ごとのヘッダーに従う。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분Ownership持株Samsung Bio: largest shareholder and treasury shares by quarter
기간
취득
소각
기말 자기주식
2025FY
0
0
51,433
2026H1
0
0
51,433
Period
Acquired
Cancelled
Treasury shares at period end
2025FY
0
0
51,433
2026H1
0
0
51,433
期間
取得
消却
期末自己株式
2025FY
0
0
51,433
2026H1
0
0
51,433
최신 2026H1: 삼성물산(최대주주) 43.06% · 삼성전자(계열회사) 31.22%. 자기주식 0.1% · 최대주주 변동: 2011년 04월 22일 삼성전자 40.00%; 2015년 09월 02일 삼성물산 51.04%; 2025년 11월 03일 삼성물산 43.06%.
⚠ Discipline: Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.
⚠ 規律:自己株式の消却は発行済株式を減らし、筆頭株主の持株比率を上げる。
Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in group '삼성')Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in its business group)Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in its business group)
삼성물산(주) → 삼성바이오로직스㈜ 43.10% · 삼성전자(주) → 삼성바이오로직스㈜ 31.20%. 해외 계열 출자 774건.
⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).
⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수주Orders受注Samsung Bio: contract total, delivered and backlog (order table, USD)
최신 26Q2: CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — 총액 21,689 · 기납품 11,766 · 잔고 9,923 (USD 백만) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — 총액 24,292 · 기납품 11,766 · 잔고 12,526 (USD 백만)
Latest 26Q2: CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — total 21,689 · delivered 11,766 · backlog 9,923 (USD mn) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — total 24,292 · delivered 11,766 · backlog 12,526 (USD mn)
最新26Q2:CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — 総額21,689 · 納品済み11,766 · 残高9,923(USD百万) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — 総額24,292 · 納品済み11,766 · 残高12,526(USD百万)
⚠ 규율: 삼성바이오로직스는 '최소구매물량 기준'과 '고객사 제품개발 성공 시 예상 수요물량 기준' 두 줄을 낸다 — 차트는 앞의 것(계약상 확정분).
⚠ Discipline: Samsung Biologics reports two lines, 'minimum purchase volume basis' and 'expected demand if the client's product development succeeds' — the chart uses the first (contractually committed).
Limitations: 각 보고서 '수주상황' 표 · 삼성바이오로직스는 최소구매물량 기준 줄 · 수주 잔고 정의는 회사 기재 그대로.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The 'order status' table in each report · for Samsung Biologics, the minimum-purchase-volume line · the backlog definition is as the company states it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
설비Plant設備Samsung Bio: capacity, output and utilization (annual report tables)
표
항목
당기
전기
전전기
production
생산능력
1,034.0
833.0
733.0
production
생산실적
733.0
626.0
523.0
production
가동률
70.9
75.2
71.4
utilization
생산능력
1,034.0
833.0
733.0
utilization
생산실적
733.0
626.0
523.0
utilization
가동률
70.9
75.2
71.4
Table
Item
Current period
Prior period
Two periods ago
Output
생산능력
1,034.0
833.0
733.0
Output
생산실적
733.0
626.0
523.0
Output
가동률
70.9
75.2
71.4
Utilisation
생산능력
1,034.0
833.0
733.0
Utilisation
생산실적
733.0
626.0
523.0
Utilisation
가동률
70.9
75.2
71.4
表
項目
当期
前期
前々期
生産実績
생산능력
1,034.0
833.0
733.0
生産実績
생산실적
733.0
626.0
523.0
生産実績
가동률
70.9
75.2
71.4
稼働率
생산능력
1,034.0
833.0
733.0
稼働率
생산실적
733.0
626.0
523.0
稼働率
가동률
70.9
75.2
71.4
생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).
Capacity, output and utilisation tables (units as in each table: batches etc.).
生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。
Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
구조Structure構造Samsung Bio: structural events, pipeline and licenses (annual report text)
인적분할: 34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur 인적분할: 34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202
Spin-off: 34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur Spin-off: 34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202
人的分割:34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur 人的分割:34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202
⚠ 규율: 파이프라인 0건 · 라이선스 아웃 0건 · 인 24건(원문 표 기준).
⚠ Discipline: Pipeline 0 · licence-out 0 · licence-in 24 (as in the original tables).
⚠ 規律:パイプライン0件 · ライセンスアウト0件 · イン24件(原文の表ベース)。
Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
07
대웅(지주) — 심층Daewoong (hold.) — deep diveDaewoong (hold.) — 深掘り
분기Quarterly四半期Daewoong (hold.): quarterly revenue and operating income
Limitations: 연결 분기 손익 · 4분기 = 연간 − 9개월 누계 · 합병 해(셀트리온 2023)는 앞뒤 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated quarterly income statement · Q4 = full year − nine-month cumulative · the merger year (Celltrion 2023) differs in scope from the years around it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지주 가치Holding value持株会社の価値Daewoong (hold.): what the market pays for the holding vs. the market value of the listed stakes it owns
보유 상장 지분
지분율
시가
피출자 시총
지분율 출처
대웅제약
52.29%
0.630조
1.21조
피출자 최대주주 표
광동제약
4.60%
0.015조
0.33조
대웅 타법인 출자 현황
지구홀딩스
15.00%
0.008조
0.05조
대웅 타법인 출자 현황
(대웅제약 보유) 한올바이오파마
30.80%
0.751조
2.44조
피출자 최대주주 표
(대웅제약 보유) 인벤티지랩
0.30%
0.001조
0.28조
대웅제약 타법인 출자 현황
(대웅제약 보유) 씨어스
2.60%
0.015조
0.57조
대웅제약 타법인 출자 현황
KRX 시가총액 2026-11-10 · 지분율 = 피출자 최대주주 표 우선
Listed stake held
Stake
Market value
Investee market cap
Source of the stake
Daewoong Pharma
52.29%
KRW 0.630trn
KRW 1.21trn
investee's largest-shareholder table
Kwangdong Pharmaceutical
4.60%
KRW 0.015trn
KRW 0.33trn
Daewoong (hold.)'s investments in other companies
ZGOO Holdings
15.00%
KRW 0.008trn
KRW 0.05trn
Daewoong (hold.)'s investments in other companies
(held by Daewoong Pharm) Hanall Biopharma
30.80%
KRW 0.751trn
KRW 2.44trn
investee's largest-shareholder table
(held by Daewoong Pharm) Inventage Lab
0.30%
KRW 0.001trn
KRW 0.28trn
Daewoong Pharm's investments in other companies
(held by Daewoong Pharm) Seers
2.60%
KRW 0.015trn
KRW 0.57trn
Daewoong Pharm's investments in other companies
KRX market cap 2026-11-10 · stake = the investee's largest-shareholder table first
保有上場株式
持株比率
時価
出資先の時価総額
持株比率の出所
Daewoong Pharma
52.29%
0.630兆ウォン
1.21兆ウォン
出資先の筆頭株主表
Kwangdong Pharmaceutical
4.60%
0.015兆ウォン
0.33兆ウォン
Daewoong (hold.)の他法人出資状況
ZGOO Holdings
15.00%
0.008兆ウォン
0.05兆ウォン
Daewoong (hold.)の他法人出資状況
(Daewoong Pharm保有)Hanall Biopharma
30.80%
0.751兆ウォン
2.44兆ウォン
出資先の筆頭株主表
(Daewoong Pharm保有)Inventage Lab
0.30%
0.001兆ウォン
0.28兆ウォン
Daewoong Pharmの他法人出資状況
(Daewoong Pharm保有)Seers
2.60%
0.015兆ウォン
0.57兆ウォン
Daewoong Pharmの他法人出資状況
KRX時価総額2026-11-10 · 持株比率 = 出資先の筆頭株主表を優先
대웅(지주) 시총 0.94조 중 자기주식이 27.7%다(12종목 중 1위 · 다음은 유한양행 7.6%). 자기주식 뺀 시총 0.68조 ≈ 상장 지분 시가 0.65조(대웅제약 52.29% = 0.63조 · 광동제약 4.60% = 0.015조 · 지구홀딩스 15.00% = 0.008조) → 96%. 비상장 100% 자회사 대웅바이오(최근 사업연도 순이익 569억 · 장부 589억)·대웅개발(장부 1,055억)과 지주 자체 순현금(138억, 2026H1)이 시총에 거의 값이 매겨지지 않은 셈이다. 한 층 아래 대웅제약도 시총 1.21조 중 한올바이오파마 지분(30.8%) 시가가 0.75조(62%) — 한올을 빼면 0.45조.
Of Daewoong (hold.)'s market cap of KRW 0.94trn, treasury shares are 27.7% (rank 1 of 12 companies · next is Yuhan at 7.6%). Market cap excluding treasury shares KRW 0.68trn ≈ market value of the listed stakes KRW 0.65trn (Daewoong Pharm 52.29% = KRW 0.63trn · Kwangdong Pharmaceutical 4.60% = KRW 0.015trn · ZGOO Holdings 15.00% = KRW 0.008trn) → 96%. The unlisted wholly owned subsidiaries Daewoong Bio (net profit in the latest fiscal year 569 KRW 100mn · book value 589 KRW 100mn) and Daewoong Development (book value 1,055 KRW 100mn), together with the holding company's own net cash (138 KRW 100mn, 2026H1), are in effect barely valued in the market cap. One level down, the stake in HanAll (30.8%) is worth KRW 0.75trn of Daewoong Pharm's KRW 1.21trn market cap (62%) — excluding HanAll, KRW 0.45trn.
⚠ Discipline: Treasury shares carry no votes or dividends — they have to be taken out of the market cap before comparing. Daewoong (hold.)'s treasury shares are falling through disposals, not cancellations (recent: 2022FY disposal 15,649 shares; 2024FY disposal 690,630 shares; 2025FY disposal 581,420 shares). The value of the unlisted subsidiaries is not assessed (only book value and net profit are carried over).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: Market value = stake × the investee's KRX market cap · Daewoong (hold.)'s market cap is compared as all listed shares × (1 − treasury-share ratio) · for unlisted subsidiaries only the book value and latest-fiscal-year net profit from 'investments in other companies' are carried over (not a valuation) · taxes and control premiums are not considered.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수익률Returns収益率Daewoong (holding, consolidated) and Daewoong Pharm: ROIC and ROE
FY2025: 대웅 ROIC 13.3% · ROE 16.1% · 대웅제약 ROIC 14.4% · ROE 21.8%. 최근 4분기: 대웅 11.0%/14.8% · 대웅제약 12.3%/18.9%. FY24 에 ROE 가 꺼진 것은 영업이 아니라 영업외 — 대웅제약 세전 566억 vs 영업이익 1,479억.
FY2025: Daewoong (hold.) ROIC 13.3% · ROE 16.1% · Daewoong Pharm ROIC 14.4% · ROE 21.8%. Last four quarters: Daewoong (hold.) 11.0%/14.8% · Daewoong Pharm 12.3%/18.9%. ROE dipped in FY24 because of non-operating items, not operations — Daewoong Pharm pre-tax profit 566 KRW 100mn vs operating profit 1,479 KRW 100mn.
⚠ 규율: 지주(대웅) 연결엔 대웅제약·한올바이오파마·대웅바이오가 들어 있다 — 지주 ROE 의 상당 부분이 자회사 이익이다.
⚠ Discipline: The holding company's (Daewoong (hold.)) consolidated figures include Daewoong Pharm, HanAll and Daewoong Bio — a large part of the holding company's ROE is subsidiary earnings.
Limitations: 연결 · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산·영업권 + 운전자본) · ROE = 지배주주 순이익 ÷ 평균 지배주주 자본 · TTM = 최근 4분기(분기보고서).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets and goodwill + working capital) · ROE = net profit attributable to owners of the parent ÷ average equity attributable to owners · TTM = last four quarters (quarterly reports).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
투입·산출Inputs vs outputs投入と産出Daewoong Pharm: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2019–FY2025
FY
매출
영업이익
설비투자
유형자산
인원
인건비
1인당 매출
인건비/매출
판정
FY2019
—
—
—
—
—
—
7.6억
8.5%
—
FY2020
-5.2%
-62.0%
19.1%
-0.3%
-3.3%
-2.3%
7.5억
8.8%
미달
FY2021
9.2%
423.6%
25.3%
0.5%
6.7%
9.4%
7.6억
8.8%
미달
FY2022
11.0%
7.8%
51.5%
11.5%
8.9%
16.7%
7.8억
9.3%
미달
FY2023
7.4%
28.0%
37.8%
19.7%
5.4%
7.2%
7.9억
9.2%
미달
FY2024
3.4%
20.7%
46.6%
26.8%
1.4%
5.5%
8.1억
9.4%
미달
FY2025
10.4%
33.0%
5.4%
25.7%
2.1%
3.7%
8.8억
8.9%
미달
전년 대비 증가율 · 매출·영업이익·설비투자·유형자산 = 연결 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신, 기간제 포함) · * = 합병이 낀 해
FY
Revenue
Operating profit
Capex
PP&E
Headcount
Payroll
Revenue per head
Payroll / revenue
Verdict
FY2019
—
—
—
—
—
—
7.6 KRW 100mn
8.5%
—
FY2020
-5.2%
-62.0%
19.1%
-0.3%
-3.3%
-2.3%
7.5 KRW 100mn
8.8%
fail
FY2021
9.2%
423.6%
25.3%
0.5%
6.7%
9.4%
7.6 KRW 100mn
8.8%
fail
FY2022
11.0%
7.8%
51.5%
11.5%
8.9%
16.7%
7.8 KRW 100mn
9.3%
fail
FY2023
7.4%
28.0%
37.8%
19.7%
5.4%
7.2%
7.9 KRW 100mn
9.2%
fail
FY2024
3.4%
20.7%
46.6%
26.8%
1.4%
5.5%
8.1 KRW 100mn
9.4%
fail
FY2025
10.4%
33.0%
5.4%
25.7%
2.1%
3.7%
8.8 KRW 100mn
8.9%
fail
Year-on-year growth · revenue, operating profit, capex and PP&E = consolidated · headcount and payroll = 'employee status' in the annual report (the company itself, fixed-term staff included) · * = year that includes a merger
⚠ 규율: 판정 = 그해 매출·영업이익 증가율(작은 쪽)이 설비투자·유형자산·인원·인건비 증가율(큰 쪽)을 넘었나 — 엄격한 잣대다. 표에서 어느 투입이 막았는지 본다.
⚠ Discipline: Verdict = did that year's growth in revenue and operating profit (the smaller of the two) exceed the growth in capex, PP&E, headcount and payroll (the largest)? It is a strict test. The table shows which input held it back.
Limitations: 매출·영업이익·설비투자·유형자산 = 연결 재무제표 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신만 — 해외 판매법인 인원은 빠진다) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 합병이 낀 해는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Revenue, operating profit, capex and PP&E = consolidated financial statements · headcount and payroll = 'employee status' in the annual report (the company itself only — staff at overseas sales subsidiaries are excluded) · average annual = compound growth between the first and last year · years that include a merger mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
밸류ValuationバリュエーションDaewoong (holding) and Daewoong Pharm: trailing P/E and P/B on KRX market cap (treasury excluded)
회사
KRX 시총
자기주식
자기주식 뺀 시총
최근 4분기 순이익
P/E
P/E(세후 영업이익)
P/B
이익수익률
대웅(지주)
0.94조
27.7%
0.68조
1,794억
3.8배
3.0배
0.54배
26.5%
대웅제약
1.21조
0.7%
1.20조
1,955억
6.1배
6.3배
1.12배
16.3%
KRX 2026-11-10 · 순이익 = 지배주주
Company
KRX market cap
Treasury shares
Market cap ex-treasury
Net profit, last 4 quarters
P/E
P/E (after-tax operating profit)
P/B
Earnings yield
Daewoong (hold.)
KRW 0.94trn
27.7%
KRW 0.68trn
1,794 KRW 100mn
3.8x
3.0x
0.54x
26.5%
Daewoong Pharm
KRW 1.21trn
0.7%
KRW 1.20trn
1,955 KRW 100mn
6.1x
6.3x
1.12x
16.3%
KRX 2026-11-10 · net profit = attributable to owners
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX 시가총액 × (1 − 자기주식 비율) · 순이익 = 분기보고서 지배주주 순이익 최근 4분기 · 세후 영업이익 = 영업이익 × (1 − FY 유효세율) · 지주 연결 순이익엔 자회사 몫이 들어 있다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX market cap × (1 − treasury-share ratio) · net profit = net profit attributable to owners from the quarterly reports, last four quarters · after-tax operating profit = operating profit × (1 − FY effective tax rate) · the holding company's consolidated net profit includes the subsidiaries' share.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분 사슬Ownership chain持株チェーンDaewoong (hold.): economic interest of the controlling family vs. voting control (look-through)
첫 단계 보유자
관계
지분율
자기주식 뺀 몫
그 경로로 가족에게
경로
윤재승
본인
11.64%
16.10%
16.10%
가족
대웅재단
재단
9.98%
13.80%
0.00%
재단
윤재용
친인척
7.01%
9.70%
9.70%
가족
윤영
친인척
5.42%
7.50%
7.50%
가족
(주)하나누리
기타
1.77%
2.45%
0.00%
비상장 법인(위 확인 안 함)
(주)디엔홀딩스
기타
1.77%
2.45%
0.00%
비상장 법인(위 확인 안 함)
(주)블루넷
기타
0.26%
0.36%
0.00%
비상장 법인(위 확인 안 함)
윤재춘
임원
0.08%
0.11%
0.00%
임원
경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준
First-tier holder
Relation
Stake
Share ex-treasury
To the family via this path
Path
Yun Jaeseung
self
11.64%
16.10%
16.10%
family
Daeungjaedan
foundation
9.98%
13.80%
0.00%
foundation
Yun Jaeyong
relative
7.01%
9.70%
9.70%
family
Yun Yeong
relative
5.42%
7.50%
7.50%
family
Hananuri
other
1.77%
2.45%
0.00%
unlisted corporate (owners not checked)
Dienholdingseu
other
1.77%
2.45%
0.00%
unlisted corporate (owners not checked)
Beul Runet
other
0.26%
0.36%
0.00%
unlisted corporate (owners not checked)
Yun Jaechun
executive
0.08%
0.11%
0.00%
executive
Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1
최대주주 측 38.0% · 자기주식 27.7% → 의결권 기준 52.6%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 33.3% (윤재승 16.1% · 윤재용 9.7% · 윤영 7.5% · 윤수민 0.0% · 윤수진 0.0%) → 지배-소유 괴리 19.3%p. 위를 모르는 비상장 법인 (주)블루넷, (주)하나누리, (주)디엔홀딩스 몫 5.3%는 그 주주가 Raw Data 에 없어 가족 몫에 넣지 못했다(확인 안 함) — 가족 몫은 하한이다. 추이: 2019Q1 최대주주 본인 11.61% · 측 합 38.14% → 2026H1 11.64% · 38.04%. 이 회사가 가진 상장 지분 시가 0.65조 = 자기주식 뺀 시총의 96%.
Largest-shareholder group 38.0% · treasury shares 27.7% → 52.6% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 33.3% (Yun Jaeseung 16.1% · Yun Jaeyong 9.7% · Yun Yeong 7.5% · Yun Sumin 0.0% · Yun Sujin 0.0%) → control–ownership wedge 19.3pp. The 5.3% held by unlisted corporates whose owners are unknown (Beul Runet, Hananuri, Dienholdingseu) could not be added to the family's share because their shareholders are not in the Raw Data (not checked) — the family share is a lower bound. Trend: 2019Q1 largest shareholder alone 11.61% · group total 38.14% → 2026H1 11.64% · 38.04%. Market value of the listed stakes this company owns: KRW 0.65trn = 96% of its market cap excluding treasury shares.
⚠ 규율: 윤재승 개인의 경제적 몫은 대웅 16.1% · 대웅제약 8.6% · 한올바이오파마 2.7% — 내려갈수록 줄고, 의결권 기준 지배 측은 52.6% · 61.8% · 32.0%로 그대로다.
⚠ Discipline: Yun Jaeseung's personal economic interest is 16.1% in Daewoong (hold.) · 8.6% in Daewoong Pharm · 2.7% in HanAll — it shrinks further down the chain, while the controlling side on a voting basis stays at 52.6% · 61.8% · 32.0%.
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
운전자본Working capital運転資本Daewoong (hold.): inventory and receivable days, net debt
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분Ownership持株Daewoong (hold.): largest shareholder and treasury shares by quarter
⚠ Discipline: Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.
⚠ 規律:自己株式の消却は発行済株式を減らし、筆頭株主の持株比率を上げる。
Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⚠ 규율: 이 그룹은 '계열회사간 출자현황'을 그림으로만 공시한다 — 각 회사 DART 최대주주 표(2026H1)를 이름으로 이었다. 개인 → 지주 → 사업회사 → 손자회사 순.
⚠ Discipline: This group files its 'cross-shareholdings among affiliates' only as an image — we joined each company's DART largest-shareholder table (2026H1) by name. Order: individuals → holding company → operating company → second-tier subsidiary.
Limitations: 각 회사 DART 최대주주 현황(보통주, 최신 분기)을 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Each company's DART largest-shareholder table (common shares, latest quarter) joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
설비Plant設備Daewoong (hold.): capacity, output and utilization (annual report tables)
표
항목
당기
전기
전전기
capacity
8시간 / 161시간 / 1,936시간
production
의약품
1,936.0
1,160.0
60.0
utilization
의약품
1,936.0
1,160.0
60.0
Table
Item
Current period
Prior period
Two periods ago
Capacity
8시간 / 161시간 / 1,936시간
Output
의약품
1,936.0
1,160.0
60.0
Utilisation
의약품
1,936.0
1,160.0
60.0
表
項目
当期
前期
前々期
生産能力
8시간 / 161시간 / 1,936시간
生産実績
의약품
1,936.0
1,160.0
60.0
稼働率
의약품
1,936.0
1,160.0
60.0
생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).
Capacity, output and utilisation tables (units as in each table: batches etc.).
生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。
Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
구조Structure構造Daewoong (hold.): structural events, pipeline and licenses (annual report text)
구 분
품 목
적응증
연구시작일
현재 진행단계
비 고
바이오
신약
HL036
안구건조증
2016년
임상 3-3상(미국)
DWP457
1, 2형 당뇨병
2013년
전임상
-
-
DWP713
입술 볼륨 증대
2021년
비임상
-
공동연구(시지바이오)
DWP714
연골조직수복
2021년
비임상
-
공동연구(시지바이오)
HL186/HL187
불응성 고형암
2016년
HL186: 후보물질도출(중단)HL187: 전임상(중단)
-
공동연구(한올바이오파마)
DWP817S004
근감소증
2022년
비임상
-
-
DWP431
퇴행성 추간판 질환(Degenerative DiscDisease)
2019년
융복합의료기기 임상시험(IDE) 신청 승인(미국)
2025년 4월
공동연구(시지바이오)
Biologics
DWP450(나보타)
미간주름
2012년
품목허가(한국)
2013년 11월
2013년
품목허가(캐나다)품목허가(미국)품목허가(EU)
2018년 8월2019년 2월2019년 9월
-
2015년
품목허가 신청(중국)
-
-
뇌졸중 후 상지근육경직
2013년
적응증 추가(한국)
2015년 11월
-
눈가주름(외안각주름)
2016년
적응증 추가(한국)
2018년 11월
-
합병·분할 주석 없음.
No merger or spin-off note.
合併・分割の注記なし。
⚠ 규율: 파이프라인 17건 · 라이선스 아웃 11건 · 인 2건(원문 표 기준).
⚠ Discipline: Pipeline 17 · licence-out 11 · licence-in 2 (as in the original tables).
⚠ 規律:パイプライン17件 · ライセンスアウト11件 · イン2件(原文の表ベース)。
Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
08
지분 구조 — 최대주주·자기주식Ownership structure — largest shareholders and treasury shares持株構造 — 筆頭株主・自己株式
지분Ownership持株Largest-shareholder group and treasury shares, latest quarter
Limitations: DART 최대주주 현황·주식총수(보통주) · 회사마다 기준 분기가 다를 수 있다(표의 기준 열).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder and total-shares tables (common shares) · the reference quarter may differ by company (the 'As of' column).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익의 주인Who owns the earnings利益の持ち主Who owns the earnings: look-through economic interest by holder type (treasury shares excluded)
삼성물산 가족 35.7% · 비상장 법인 0.0% · 삼성생명 가족 27.0% · 비상장 법인 0.0% · 삼성전자 가족 8.7% · 비상장 법인 0.0% · 삼성바이오로직스 가족 18.1% · 비상장 법인 0.0% · 셀트리온 가족 4.4% · 비상장 법인 28.5% · 대웅 가족 33.3% · 비상장 법인 5.3% · 대웅제약 가족 18.0% · 비상장 법인 2.8% · 한올바이오파마 가족 5.7% · 비상장 법인 0.9%.
Samsung C&T family 35.7% · unlisted corporates 0.0% · Samsung Life family 27.0% · unlisted corporates 0.0% · Samsung Elec family 8.7% · unlisted corporates 0.0% · Samsung Bio family 18.1% · unlisted corporates 0.0% · Celltrion family 4.4% · unlisted corporates 28.5% · DW Hold family 33.3% · unlisted corporates 5.3% · DW Pharm family 18.0% · unlisted corporates 2.8% · HanAll family 5.7% · unlisted corporates 0.9%.
⚠ 규율: 셀트리온의 회색(비상장 법인) 몫은 셀트리온홀딩스·스킨큐어 — 그 주주가 Raw Data 에 없어 가족 몫으로 옮기지 못했다.
⚠ Discipline: Celltrion's grey (unlisted corporates) share is Celltrion Holdings and Celltrion Skincare — their shareholders are not in the Raw Data, so it could not be moved into the family's share.
Limitations: DART 최대주주 현황(보통주)을 상장사끼리 이어 경로별 몫을 곱해 더했다 · 최대주주 표 밖의 주주는 '그 밖'에 들어간다 · 우선주·전환사채는 반영하지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares) linked between listed companies, multiplying and adding the share along each path · shareholders outside the largest-shareholder tables fall under 'Other shareholders' · preferred shares and convertible bonds are not reflected.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지배 vs 소유Control vs ownership支配 vs 所有Voting control of the controlling group vs. the family's economic interest
삼성물산 지배 37.7% vs 몫 35.7% (괴리 2.0%p) · 삼성생명 지배 48.5% vs 몫 27.0% (괴리 21.5%p) · 삼성전자 지배 20.0% vs 몫 8.7% (괴리 11.2%p) · 삼성바이오로직스 지배 74.4% vs 몫 18.1% (괴리 56.3%p) · 셀트리온 지배 33.2% vs 몫 4.4% (괴리 28.8%p) · 대웅 지배 52.6% vs 몫 33.3% (괴리 19.3%p) · 대웅제약 지배 61.8% vs 몫 18.0% (괴리 43.8%p) · 한올바이오파마 지배 32.0% vs 몫 5.7% (괴리 26.4%p).
Samsung C&T control 37.7% vs interest 35.7% (wedge 2.0pp) · Samsung Life control 48.5% vs interest 27.0% (wedge 21.5pp) · Samsung Elec control 20.0% vs interest 8.7% (wedge 11.2pp) · Samsung Bio control 74.4% vs interest 18.1% (wedge 56.3pp) · Celltrion control 33.2% vs interest 4.4% (wedge 28.8pp) · DW Hold control 52.6% vs interest 33.3% (wedge 19.3pp) · DW Pharm control 61.8% vs interest 18.0% (wedge 43.8pp) · HanAll control 32.0% vs interest 5.7% (wedge 26.4pp).
Samsung C&T 支配37.7% vs 持分35.7%(乖離2.0%pt) · Samsung Life 支配48.5% vs 持分27.0%(乖離21.5%pt) · Samsung Elec 支配20.0% vs 持分8.7%(乖離11.2%pt) · Samsung Bio 支配74.4% vs 持分18.1%(乖離56.3%pt) · Celltrion 支配33.2% vs 持分4.4%(乖離28.8%pt) · DW Hold 支配52.6% vs 持分33.3%(乖離19.3%pt) · DW Pharm 支配61.8% vs 持分18.0%(乖離43.8%pt) · HanAll 支配32.0% vs 持分5.7%(乖離26.4%pt)。
⚠ 규율: 괴리가 큰 곳일수록 가족이 적은 경제적 몫으로 많은 의결권을 쥔다(계열사·재단을 거쳐). 셀트리온은 홀딩스 주주가 Raw Data 에 없어 괴리가 실제보다 크게 나온다.
⚠ Discipline: The wider the wedge, the more votes the family holds with a small economic interest (through affiliates and foundations). For Celltrion the wedge comes out larger than it really is because Celltrion Holdings' shareholders are not in the Raw Data.
Limitations: 의결권 기준 = 최대주주 측 지분 ÷ (1 − 자기주식 비율) · 가족 몫 = 사슬 경로별 곱의 합 · 재단·계열사 지분은 지배 측에는 들어가고 가족 몫에는 안 들어간다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Voting basis = largest-shareholder group stake ÷ (1 − treasury-share ratio) · family interest = sum of the products along the chain paths · stakes held by foundations and affiliates count towards the controlling side but not the family's interest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
親会社1社:Yuhan · 子会社(連結対象)15社:Yuhanhwahak、Yuhanmedika、Waijeumedi、Yuhangeongangsaenghwal、Aedeupama、YUHAN USA CORPORATION… · 関連会社及び共同支配企業3社:Yuhankeullorakseu(舊, Yuhankeurorakseu)、ProGen、Ryusin(chingdao)geongang(yu)。
⚠ 규율: 이 회사는 계열회사간 출자 행렬 대신 지배·종속 목록을 낸다 — 최대주주(유한재단 15.9%)는 법인이 아닌 경우 이 목록에 없다.
⚠ Discipline: This company files a parent/subsidiary list instead of a cross-shareholding matrix — the largest shareholder (Yuhanjaedan 15.9%) is not on this list if it is not a corporation.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図GC Biopharma: ownership map
㈜녹십자 → GC MOGAM, Inc. 100.00% · ㈜녹십자 → GC DO BRASIL PARTICIPACOES LTDA 99.99% · ㈜녹십자 → 농업회사법인 인백팜㈜ 89.98% · ㈜녹십자 → Curevo, Inc. 81.36% · ㈜녹십자 홀딩스 → ㈜녹십자 50.06% · ㈜녹십자 → Green Cross North America Inc 46.85% · ㈜녹십자 → ㈜녹십자엠에스 41.51% · ㈜녹십자 → ㈜녹십자랩셀 38.66%.
GC Biopharma → GC MOGAM, Inc. 100.00% · GC Biopharma → GC DO BRASIL PARTICIPACOES LTDA 99.99% · GC Biopharma → Nongeophoesabeopin Inbaekpam 89.98% · GC Biopharma → Curevo, Inc. 81.36% · GC → GC Biopharma 50.06% · GC Biopharma → Green Cross North America Inc 46.85% · GC Biopharma → GC Medical Science 41.51% · GC Biopharma → Noksipjaraepsel 38.66%.
GC Biopharma → GC MOGAM, Inc. 100.00% · GC Biopharma → GC DO BRASIL PARTICIPACOES LTDA 99.99% · GC Biopharma → Nongeophoesabeopin Inbaekpam 89.98% · GC Biopharma → Curevo, Inc. 81.36% · GC → GC Biopharma 50.06% · GC Biopharma → Green Cross North America Inc 46.85% · GC Biopharma → GC Medical Science 41.51% · GC Biopharma → Noksipjaraepsel 38.66%。
⚠ 규율: 원문 '계열회사간 출자현황'(FY2020). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2020). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図Chong Kun Dang: ownership map
Chongkundang Holdings → Chong Kun Dang Pharmaceutical 26.70% · I Janghan → Chong Kun Dang Pharmaceutical 9.55% · I Juwon → Chong Kun Dang Pharmaceutical 1.48% · I Jugyeong → Chong Kun Dang Pharmaceutical 1.18% · I Jua → Chong Kun Dang Pharmaceutical 1.18%.
Chongkundang Holdings → Chong Kun Dang Pharmaceutical 26.70% · I Janghan → Chong Kun Dang Pharmaceutical 9.55% · I Juwon → Chong Kun Dang Pharmaceutical 1.48% · I Jugyeong → Chong Kun Dang Pharmaceutical 1.18% · I Jua → Chong Kun Dang Pharmaceutical 1.18%。
⚠ 규율: 각 회사 DART '최대주주 현황'(2026H1)을 이름으로 이어 붙였다 — 이 회사는 계열 출자 현황을 표로 내지 않는다(그림 또는 미기재). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Each company's DART 'largest shareholder status' table (2026H1) joined by name — this company does not file its affiliate shareholdings as a table (image only or not stated). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⚠ 규율: 각 회사 DART '최대주주 현황'(2026H1)을 이름으로 이어 붙였다 — 이 회사는 계열 출자 현황을 표로 내지 않는다(그림 또는 미기재). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Each company's DART 'largest shareholder status' table (2026H1) joined by name — this company does not file its affiliate shareholdings as a table (image only or not stated). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図SK Biopharm: ownership map
SK(주) → SK바이오팜 64.00%.
SK → SKbaiopam 64.00%.
SK → SKbaiopam 64.00%。
⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분도Ownership map持株関係図SK Bioscience: ownership map
SK케미칼 → SK바이오사이언스 66.40%.
SK Chemicals → SK Bioscience 66.40%.
SK Chemicals → SK Bioscience 66.40%。
⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.
⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
09
Raw Data 상태Raw Data statusRaw Dataの状態
검증Check検証Ledger status
셀트리온: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 삼성바이오: 패널 FY2019~2025 PASS1 OK · 원문 31건 · 유한양행: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 한미약품: 패널 FY2018~2025 PASS1 OK · 원문 30건 · SK바이오팜: 패널 FY2019~2025 PASS1 OK · 원문 25건 · SK바이오사이언스: 패널 FY2021~2025 PASS1 OK · 원문 31건 · GC녹십자: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 종근당: 패널 FY2018~2025 PASS1 OK · 원문 30건 · 대웅제약: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 대웅(지주): 패널 FY2018~2025 PASS1 OK · 원문 31건 · 한올바이오파마: 패널 FY2018~2025 PASS1 OK · 원문 31건 · SD바이오센서: 패널 FY2020~2025 PASS1 OK · 원문 23건.
Celltrion: panel FY2018–2025 PASS1 OK · original filings 31 · Samsung Bio: panel FY2019–2025 PASS1 OK · original filings 31 · Yuhan: panel FY2018–2025 PASS1 OK · original filings 31 · Hanmi: panel FY2018–2025 PASS1 OK · original filings 30 · SK Biopharm: panel FY2019–2025 PASS1 OK · original filings 25 · SK Bioscience: panel FY2021–2025 PASS1 OK · original filings 31 · GC Biopharma: panel FY2018–2025 PASS1 OK · original filings 31 · Chong Kun Dang: panel FY2018–2025 PASS1 OK · original filings 30 · Daewoong Pharm: panel FY2018–2025 PASS1 OK · original filings 31 · Daewoong (hold.): panel FY2018–2025 PASS1 OK · original filings 31 · HanAll: panel FY2018–2025 PASS1 OK · original filings 31 · SD Biosensor: panel FY2020–2025 PASS1 OK · original filings 23.
Celltrion:パネルFY2018〜2025 PASS1 OK · 原文31件 · Samsung Bio:パネルFY2019〜2025 PASS1 OK · 原文31件 · Yuhan:パネルFY2018〜2025 PASS1 OK · 原文31件 · Hanmi:パネルFY2018〜2025 PASS1 OK · 原文30件 · SK Biopharm:パネルFY2019〜2025 PASS1 OK · 原文25件 · SK Bioscience:パネルFY2021〜2025 PASS1 OK · 原文31件 · GC Biopharma:パネルFY2018〜2025 PASS1 OK · 原文31件 · Chong Kun Dang:パネルFY2018〜2025 PASS1 OK · 原文30件 · Daewoong Pharm:パネルFY2018〜2025 PASS1 OK · 原文31件 · Daewoong (hold.):パネルFY2018〜2025 PASS1 OK · 原文31件 · HanAll:パネルFY2018〜2025 PASS1 OK · 原文31件 · SD Biosensor:パネルFY2020〜2025 PASS1 OK · 原文23件。
Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
∞
천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと
시세(KRX 시가총액)는 심층 세 종목(셀트리온·삼성바이오로직스·대웅)과 지분 사슬 카드에만 붙였다. 나머지 회사의 이익수익률은 배당 있는 회사만(배당수익률로 역산).
지분 사슬은 상장사 최대주주 표까지. 셀트리온홀딩스·셀트리온스킨큐어·하나누리·디엔홀딩스 같은 비상장 법인의 주주는 Raw Data 에 없다(확인 안 함) — 그 위 개인 몫은 빠진다.
잠정실적은 회사 발표값이다. 외부감사인 검토 전 — 분기보고서가 나오면 그 값으로 바꾼다.
관세청 수출은 한국 전체다. 삼성바이오로직스 몫을 가르지 못한다 — 우리 Fcst 는 과거 탄력성으로 잇는 추정이다.
합병·분할 해는 성장이 아니다. 셀트리온 2023(헬스케어 합병), 삼성바이오로직스 2025(에피스 인적분할·재표시).
R&D 표는 회사 서식. 옛 해(2019~21)와 일부 회사는 아직 못 잡았다. 파이프라인·라이선스는 목록만(가치 평가 없음).
셀트리온 관세청 연결은 우리 Fcst 를 내지 않았다. 합병 뒤 전진 검증에서 직전 분기 유지를 과반 분기에서 못 이겼다.
도쿄해상·EDINET 트랙과 별개.
Market prices (KRX market cap) are attached only to the three deep-dive companies (Celltrion, Samsung Biologics, Daewoong) and to the ownership-chain cards. For the other companies the earnings yield covers dividend payers only (backed out from the dividend yield).
The ownership chain stops at the listed companies' largest-shareholder tables. The shareholders of unlisted corporates such as Celltrion Holdings, Celltrion Skincare, Hananuri and DN Holdings are not in the Raw Data (not checked) — the individuals' share above them is missing.
Preliminary results are company announcements. They come before the external auditor's review and are replaced once the quarterly report is out.
Customs exports are Korea-wide. Samsung Biologics' share cannot be separated out — our Fcst is an estimate that carries past elasticity forward.
A merger or spin-off year is not growth. Celltrion 2023 (Celltrion Healthcare merger), Samsung Biologics 2025 (Samsung Bioepis spin-off and restatement).
The R&D tables follow each company's own format. Older years (2019–21) and some companies are not yet captured. Pipelines and licences are lists only (no valuation).
The Celltrion customs link did not produce our Fcst. In the post-merger forward test it did not beat holding the previous quarter in a majority of quarters.
Source: DART, Financial Supervisory Service. 출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13 Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis. Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr). Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.